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1. ALLERGY AND INFLAMMATION: a complex immune origin disease 
The   term   ‘allergy’   was   coined   by   Clemens   von   Pirquet   in   1906   to   call   attention   to   the unusual 
propensity of some individuals to develop   signs   and   symptoms   of   reactivity,   or   ‘hypersensitivity  
reactions’,  when  exposed  to  certain  substances. This term allergy can be used to refer to abnormal 
adaptive immune responses that either involve or do not involve allergen-specific IgE. Allergic 
inflammation occurs in disorders in which IgE is thought to participate. 
An abnormal adaptive immune response directed against non-infectious environmental substances 
(allergens), including non-infectious components of certain infectious organisms. In allergic 
disorders, such as anaphylaxis, allergic rhinitis (hay fever), some food allergies and allergic asthma, 
these responses are characterized by the involvement of allergen-specific IgE and T helper 2 (TH2) 
cells that recognize allergen-derived antigens. There are two main types of allergen.  
The first type encompasses any non-infectious environmental substance that can induce IgE 
production  (thereby  ‘sensitizing’  the  subject)  so  that  later  re-exposure to that substance induces an 
allergic reaction. Common sources of allergens include grass and tree pollens, animal dander 
(sheddings from skin and fur), house-dust-mite faecal particles, certain foods (notably peanuts, tree 
nuts, fish, shellfish, milk and eggs), latex, some medicines and insect venoms. In some instances, 
allergen-specific IgE directed against foreign antigens can also recognize cross-reactive host 
antigens, but the clinical significance of this is unclear. The second type is a non-infectious 
environmental substance that can induce an adaptive immune response associated with local 
inflammation but is thought to occur independently of IgE (for example, allergic contact dermatitis 
to poison ivy or nickel). 
A single allergen exposure produces an acute reaction, which is known as an early-phase reaction or 
a type I immediate hypersensitivity reaction. In many subjects, this is followed by a late-phase 
reaction. With persistent or repetitive exposure to allergen, chronic allergic inflammation develops, 
with associated tissue alterations. Early-phase reaction is an IgE-mediated type I immediate 
hypersensitivity reaction that can occur within minutes of allergen exposure. Reactions can be 
localized (for example, acute rhinoconjunctivitis in allergic rhinitis, acute asthma attacks, urticaria 
(hives) and gastrointestinal reactions in food allergies) or systemic (anaphylaxis).  
In   such   reactions,   IgE   bound   to   FcεRI   on   mast   cells   and   basophils   is   cross-linked by allergen, 
resulting   in   the   release   of   the   cells’   diverse   preformed   and   newly   synthesized  mediators.   These  
events cause vasodilation, increased vascular permeability with oedema, and acute functional 
changes in affected organs (such as bronchoconstriction, airway mucus secretion, urticaria, 
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vomiting and diarrhoea). Some of the released mediators also promote the local recruitment and 
activation of leukocytes, contributing to the development of late-phase reactions. 
Late-phase reaction is a reaction that typically develops after 2–6 h and peaks 6–9 h after allergen 
exposure. It is usually preceded by a clinically evident early-phase reaction and fully resolves in 1–
2 days. Skin late-phase reactions involve oedema, pain, warmth and erythema. 
In the lungs, these reactions are characterized by airway narrowing and mucus hypersecretion. They 
reflect the local recruitment and activation of TH2 cells, eosinophils, basophils and other 
leukocytes, and persistent mediator production by resident cells (such as mast cells). Mediators that 
initiate late-phase reactions are thought to be derived from resident mast cells activated by IgE and 
allergen or from T cells that recognize allergen-derived peptides (such T cells may be either 
resident at, or recruited to, sites of allergen challenge). 
Environmental factors appear to be more important in determining whether an atopic individual 
develops a particular allergic disease, although genetic factors may exert an influence on how 
severely the disease is expressed and the extent of the allergic inflammatory response. 
The inflammatory process has several common characteristics shared between different allergic 
diseases,  including  asthma,  allergic  rhinitis  ⁄∕  rhinosinusitis,  and  atopic dermatitis (eczema). Allergic 
inflammation is characterized by IgE-dependent activation of mucosal mast cells and an infiltration 
of eosinophils that is orchestrated by increased numbers of activated CD4+ Th2 lymphocytes. 
However, in patients with more severe disease, other cells such as neutrophils, Th1, and CD8+ 
(cytotoxic) lymphocytes may also be involved. The clinical differences between these diseases are 
largely determined by anatomical differences and the interaction between allergic inflammation and 
structural cells, such as airway smooth muscle cells in the lower airways, resulting in 
bronchoconstriction, vasodilatation in the upper airways leading to nasal blockage and rhinorrhea 
and activation of keratinocytes in the skin. The fact that there are common characteristics of allergic 
diseases suggests that it may be possible to treat these common diseases with single agents, 
particularly, as they often coexist. 
No single cell or mediator can account for all the features of allergic disease and different cells and 
mediators may be more important in one manifestation of allergic disease than another. For 
example, histamine clearly plays a key role in rhinitis yet has a relatively minor role in asthma, as 
judged by the differences in efficacy of antihistamines between these conditions. 
In allergic diseases, the inflammatory response is activated inappropriately so that it becomes 
harmful rather than protective. Allergens, such as house dust mite and pollen proteins, activate mast 
cells and eosinophil inflammation, which has evolved to kill the invading parasites and would 
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therefore be self-limiting, but in allergic disease, the non-infective inciting stimulus persists and the 
normally acute inflammatory response becomes converted into a persistent inflammation that may 
have structural consequences in the airways and skin. 
 
1.1 A COMPREHENSIVE VIEW OF ALLERGIC DISEASES 
 
Over the past decades the increasing prevalence and incidence of allergic conditions among affluent 
societies have posed a heavy burden on health care systems. The estimated prevalence of allergic 
rhinitis among 13- to 14-year-old participants of the International Study of Asthma and Allergies in 
Childhood (ISAAC) in the United States is 12% to 22%. 
Furthermore, the estimated prevalence of atopic sensitization among young adults in the United 
States is greater than 40% using the European Community Respiratory Health Survey (ECRHS) 
tools. Prevalence rates for children and adults in countries around the world differ widely. The 
ECRHS assessed geographic variations in asthma in 140,000 adults from 22 countries. 
A six fold variation in the prevalence of current asthma was found among the different participating 
countries. A high prevalence (>7%) of asthma was described in Australia, New Zealand, United 
States, Ireland, and the United Kingdom. Asthma prevalences of < 4% were found in Iceland, parts 
of Spain, Germany, Italy, Algeria and India. The ISAAC study provides the most extensive 
information for asthma in children around the world. There seems to be agreement between the 
different estimates, and the prevalence in some countries is similar to the one mentioned in the 
ECRHS study [Rigoli et al, 2011]. 
 
Allergic diseases have dramatically increased in the last decades.  A single cause of this increase 
cannot be pinpointed and experts are therefore considering the contribution of numerous factors, 
including genetics, air pollution in urban areas, pets, and early childhood exposure [Leonardi et al., 
2007]. The associated costs have increased substantially as more of the population require treatment 
for allergies [Friedlander et al., 2011].   
 
x Respiratory Allergy 
 
Rhinitis and asthma pose an important health problem with a wide range of etiologies. Allergic 
rhinitis is defined as a clinical symptomatic nasal inflammatory reaction induced by IgE-mediated 
allergen after exposure of the membranes of the nasal surface. It involves the following 
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symptomatology: itch, nasal discharge, sneezing, and nasal stuffiness. Asthma is a chronic 
inflammatory disorder of the airways with participation of various types of cells. It leads to 
recurrent episodes of wheezing, breathlessness, chest tightness and cough, usually accompanied by 
variable airflow obstruction, usually reversible with medication, as well spontaneously, and 
bronchial hyperresponsiveness against different stimuli. Allergic and infective causes are most 
common and have a substantial socioeconomic impact. 
Allergic rhinitis and asthma significantly impair quality of life and affect both school and work 
performance. 
 
A proper diagnostic of asthma and rhinitis is basic for the implementation of an appropriate 
treatment plan. Treatment of allergic rhinitis and asthma has four cornerstones: education of the 
patient, allergen avoidance measures, symptomatic treatment and allergen immunotherapy. Studies 
on the effectiveness of avoidance measures and reduction of allergens in the home environment, 
as well as the different meta-analysis conducted on these studies, have shown that, while sanitation 
and avoidance measures are effective in reducing levels of allergens, it is not accompanied by a 
substantial reduction in symptoms. 
In addition to avoidance and environmental control measures, patients should start an individualized 
pharmacological treatment. The treatment should be consistent with the severity of symptoms. 
 
 
1.2 OCULAR ALLERGIES 
Ocular allergy represents one of the most common ocular conditions encountered in clinical 
practice.  
Allergic conjunctivitis is an inclusive term that encompasses seasonal allergic conjunctivitis (SAC), 
perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), and atopic 
keratocongiuntivitis (AKC). However, AKC and VKC have clinical and pathophysiological features 
quite different from SAC and PAC, in spite of some common markers of allergy [7]. Seasonal 
allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are caused by IgE-
mediated environmental airborne allergens such as grass and tree pollens, mites, molds, and animal 
dander. A minority of allergic eye diseases are of the cell-mediated type, which may manifestsolely 
as blepharitis or blepharoconjunctivitis. The usual causes of the cell-mediated type are cosmetics, 
nickel, or topical eye medication. 
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Allergic eye inflammation is a localized allergic condition that is frequently associated with rhinitis 
and occasionally with asthma but often observed as the only or prevalent allergic manifestation. The 
symptoms and signs can manifest alone in the eyelids as atopic blepharitis or contact blepharitis. 
Lid symptoms may occur together with conjunctival symptoms. However, allergic conjunctivitis is 
the most common manifestation alone or together with lid symptoms. The eye is red and itchy, and 
there is lacrimation and slight discharge. Rubbing of the eyes, light sensitivity, redness, lacrimation, 
and lid or conjunctival edema may indicate ocular allergy. Visual acuity is usually normal. 
However, in some severe forms of allergic conjunctivitis, the cornea may be affected by atopic 
keratoconjunctivitis and vernal keratoconjunctivitis (VKC) [Kari et al., 2012]. 
 
x ETIOLOGY 
 
- Role of Mast Cell and T-Lymphocyte in Allergic Conjunctivitis 
 
Conjunctiva is the most common site for allergic reactions. It is a vascularized tissue consisting of a 
large number of dendritic cells and macrophages. These cells regulate innate and adaptive immunity 
of the conjunctival epithelium. Antigen presenting cells such as dendritic cells, B cells and 
macrophages play a key role in antigen recognition and processing by T- lymphocytes. B 
lymphocytes produce the immunological response by expressing receptors for antigen recognition 
on the cell membrane. Macrophages are another important component that regulates the production 
of major cytokines and removal of pathogens. Dendritic cells are involved in the T-helper type 2 
(Th-2) mediated allergic responses. These cells present antigen to memory T-lymphocytes, which 
produce Th-2 cytokines and also regulate the production of IL-12. In addition, conjunctival 
epidermal dendritic cells, commonly known as langerhans cells are also involved in the antigen 
processing and presenting function. Two major cell types involved in the allergic immune-
pathological response are mast cell and T-cells.  
The normal conjunctival epithelium is composed of CD4+ and CD8+ T lymphocytes. In a chronic 
allergic state memory T lymphocyte increases dramatically. 
 
- Role of Mast Cells in Allergic Eye Diseases 
 
Two different types of mast cells exist in humans, classified as MCT and MCTc subtypes on the 
basis of granule and protease content. MCT subtype contains single neutral protease or typtase, 
whereas MCTc carries both typtase and chymase. MCT subtype rises in acute inflammation while 
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an increased number of MCTc subtype is found in chronic inflammatory symptom. Mast cell 
mediated acute allergic eye diseases such as SAC and PAC are categorized as type-1 
hypersensitivity reactions. These reactions occur due to the exposure of allergens on the 
conjunctival mucus membrane and follow three phases, i.e. sensitization, early and late phases. 
In sensitization phase, allergens are processed and localized by antigen presenting cells (APC) as a 
complex of peptide fragments with MHC class-II molecules on their surface. The allergen-MHC 
class II complexes on the APC then promote the maturation of T-helper (TH) cells into Th2 cells, 
which result in the production of cytokines. These cytokines further promote the synthesis of IgE 
from B-cells. IgE binds to FcεRI receptors on mast cell, which upon subsequent exposure to 
allergens results in the cross linking of these antibodies. It changes the mast cell membrane 
permeability and results in the release of inflammatory mediators. Such inflammatory mediators 
include histamine, serotonin, leukotriene (LTC4), prostaglandin, carboxypeptidase A, platelet 
activating factor (PAF), cathepsin G, neutrophil and eosinophil. 
These inflammatory mediators contribute to the early phase response that begins within seconds of 
allergen exposure. The early phase clinical symptoms are itching, tearing, swelling, edema and 
redness. In the last phase response aggregation of FcεRI receptor initiates the breakdown of 
membrane phospholipids into inflammatory mediators such as prostaglandin, leukotrienes and 
thromboxanes that lead to late phase response via recruitment of additional inflammatory cells. The 
late phase response involves the infiltration of eosinophils,  neutrophils and basophils. 
 
- Role of T Lymphocytes in Allergic Eye Diseases 
 
Conjunctiva is a common site of allergic reactions. It is well vascularized tissue that contains large 
numbers of dendritic/ Langerhans cells and macrophages. Lymphocytes—both T and B cells—are 
important cells in allergic reactions. These are divided into CD4+ T-helper (Th) cells and CD8+ killer 
T cells. CD4+ Th cells are important in the regulation of allergic reactions. These cells can be further 
divided into Th1 and Th2 cells. Th1 cells are activated in the classic delayed-type hypersensitivity 
reaction and in some autoimmune diseases. 
The activation of Th2 cells leads to the anaphylactic type of hypersensitivity reaction. The 
subclasses of Th cells (Th1, Th2) require different kinds of cytokines to be activated. T cells start 
and regulate the immune response. Interleukin (IL)-4 has an essential role in differentiating Th cells 
into Th2 cells. The activated Th cells regulate the maturation of B lymphocytes to mature, antibody-
producing B cells and plasma cells. The maturation of B lymphocytes into IgE-producing cells 
requires, in addition to IL-4, direct contact between pre-B and Th cells. 
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The prerequisite for the immune reaction is that the antigen must be recognized and presented to the 
cells, which are responsible for the development of the immune response. 
The antigen-presenting cells in the conjunctiva are the Langerhans cells, which present the antigen 
to T lymphocytes. In the cell-mediated type of reaction (delayed type or type IV), T cells recognize 
the antigen and start the inflammatory reaction. Typical delayed-type reactions are contact 
dermatoconjunctivitis and Mantoux (tuberculin) reaction. Macrophages activated by Th cells 
destroy intracellular bacteria but also cause other delayed inflammatory reactions, including the 
contact hypersensitivity of the skin and tuberculin reaction. These reactions reach their peak in 24 to 
72 hours [Mishra et al., 2011].  
 
1.3 CELLULAR TYPES INVOLVED IN ALLERGIC REACTIONS 
 
- EOSINOPHILS 
Eosinophils were first described in 1879 by Paul Ehrlich, who noted their unusual capacity to be 
stained by acidophilic dyes. Interestingly, our appreciation of this unique property of eosinophils is 
clear and steadfast, but a comprehensive understanding of the function of these cells in health and 
disease remains elusive. Some basic characteristics of eosinophils are established and accepted. It is 
clear that eosinophils are granulocytes that develop in the bone marrow from pluripotent 
progenitors. They are released into the peripheral blood in a phenotypically mature state, and they 
are capable of being activated and recruited into tissues in response to appropriate stimuli, most 
notably the cytokine interleukin-5 (IL-5) and the eotaxin chemokines. Eosinophils spend only a 
brief time in the peripheral blood (they have a half-life of ~18 hrs) before they migrate to the 
thymus or gastrointestinal tract, where they reside under homeostatic conditions. In response to 
inflammatory stimuli, eosinophils develop from committed bone marrow progenitors, after which 
they exit the bone marrow, migrate into the blood and subsequently accumulate in peripheral 
tissues, where their survival is prolonged [Hogan, S. P. et al.,2008].  
Relatively few mature eosinophils are found in the peripheral blood of healthy humans (less than 
400 per mm3), but these cells can be readily distinguished from the more prevalent neutrophils by 
virtue of their bilobed nuclei and large specific granules (Figure 1.1). 
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Figure 1.1 The eosinophil. a | Human eosinophils from peripheral blood stained with modified Giemsa 
exhibit characteristic bilobed nuclei and large red-stained cytoplasmic secretory granules. Original 
magnification, ×100. b | The image shows eosinophils and neutrophils isolated from the spleen of a 
Cd2-interleukin-5-transgenic mouse and stained with modified Giemsa. c | The image shows a transmission 
electron micrograph of a mouse eosinophil. Cytoplasmic secretory granules are indicated by the arrows; the 
central core of these granules contains cationic major basic protein, and their periphery contains the 
remaining major cationic proteins, cytokines, chemokines, growth factors and enzymes. Original 
magnification, ×6,000. 
 
 
Human eosinophil granules contain four major proteins: eosinophil peroxidase, major basic protein 
(MBP) and the ribonucleases eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin 
(EDN). The granules also store numerous cytokines, enzymes and growth factors. Other prominent 
features of eosinophils include primary granules that contain Charcot–Leyden crystal protein (also 
known as galectin 10 and eosinophil lysophospholipase) and lipid bodies, which are the sites of 
synthesis of cysteinyl leukotrienes, thromboxane and prostaglandins. 
Eosinophils have been identified and characterized in all vertebrate species, but their morphology, 
repertoire of cell-surface receptors and intracellular contents vary significantly between species. 
Eosinophils express surface receptors for ligands that support growth, adhesion, chemotaxis, 
degranulation and cell-to-cell interactions. Of particular note, there are several crucial differences 
between mouse and human eosinophils that must be taken into account when interpreting mouse 
model studies of human disease (Figure 1.1).  
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Figure 1.2 Eosinophils are equipped with features that promote interactions with the environment. In one 
such interaction, eosinophils release the contents of their specific granules in response to external stimuli. 
Some of these granule contents are released via membrane-bound vesicles known as eosinophil sombrero 
vesicles. Eosinophils also synthesize lipid mediators for release in cytoplasmic lipid bodies and store 
Charcot–Leyden crystal protein (CLC) in primary granules. Although not highly biosynthetic, mature 
eosinophils have minimal numbers of mitochondria and a limited endoplasmic reticulum (ER) and Golgi, as 
well as a nucleus. Eosinophils express a wide variety of receptors that modulate adhesion, growth, survival, 
activation,   migration   and   pattern   recognition.  Mouse   eosinophils   do   not   express   CLC   or   Fcε   receptor   1  
(FcεR1)  and  have  divergent  homologues  of  sialic  acid-binding immunoglobulin-like lectin 8 (SIGLEC-8) and 
the granule ribonucleases eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP)12. 
APRIL, a proliferation-inducing ligand; CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; CXCL, 
CXC-chemokine ligand; CXCR, CXC-chemokine receptor; EGF, epidermal growth factor; EPX, eosinophil 
peroxidase; FPR1, formyl peptide receptor 1; GM-CSF, granulocyte–macrophage colony-stimulating factor; 
IFN, interferon; IL, interleukin; MBP, major basic protein; NGF, nerve growth factor; NOD, nucleotide-
binding oligomerization domain protein; PAR, proteinase-activated receptor; PDGF, platelet-derived 
growth factor; PIRB, paired immunoglobulin-like   receptor   B;;   PPARγ,   peroxisome   proliferator-activated 
receptor-γ;;  PRR,  pattern-recognition receptor; PSGL1, P-selectin glycoprotein ligand 1; RAGE, receptor for 
advanced glycation end-products; RIG-I, retinoic acid-inducible gene I; TGF, transforming growth factor; 
TLR, Toll-like receptor; TNF, tumour necrosis factor; SCF, stem cell factor; VEGF, vascular endothelial 
growth factor. 
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The life cycle of the eosinophil is divided into bone marrow, blood, and tissue phases. Eosinophils 
are produced in bone marrow from pluripotential stem cells. The stem cells differentiate into a 
progenitor, which is capable of giving rise to mixed colonies of basophils and eosinophils, pure 
basophil colonies, or pure eosinophil colonies. Among various hematopoietic factors, those 
important for eosinophil proliferation and differentiation are interleukin (IL)-3, granulocyte-
macrophage colony-stimulating factor (GM-CSF), and IL-5. IL-3 and GM-CSF are relatively 
nonspecific and stimulate proliferation of neutrophils, basophils, and eosinophils. In contrast, IL-5 
potently and specifically stimulates eosinophil production. 
Although the eosinophil is a formed element of the peripheral circulation, it is primarily a tissue-
dwelling cell. In healthy individuals, most eosinophils are found in the gut (but not the esophagus), 
mammary gland, uterus, thymus and bone marrow; the gastrointestinal eosinophil is the 
predominant population of eosinophils. At baseline condition, eosinophils are present in the 
gastrointestinal tract independent of adaptive immunity and enteric flora, and the eosinophil levels 
are regulated by the constitutive expression of eotaxin-1 and eosinophil chemokine receptor, CCR3. 
Eosinophils also home into the thymus, mammary gland, and uterus, as controlled by eotaxin-1. 
Eosinophils also interact with and modulate the functions of other leukocytes. 
 
- Interaction with lymphocytes  
Eosinophils clearly respond to signals (such as IL-5) that are provided by T cells. Two recent 
studies indicate that T cells also respond to signals provided by eosinophils. Although not 
‘professional’   antigen-presenting cells, eosinophils can express cell-surface components that are 
required for antigen presentation (such as MHC class II molecules and the co-stimulatory molecules 
CD80 and CD86). Indeed, eosinophils can process antigens and stimulate T cells in an antigen-
specific manner, resulting in T cell proliferation and cytokine release. In addition, eosinophils 
release preformed cytokines (such as IL-4, IL-13 and IFNγ) that promote either TH2 or TH1 cell 
responses.  
Eosinophils also promote humoral immune responses. Indeed, they are capable of priming B cells 
for the production of antigen-specific IgM43. Eosinophils communicate extensively with tissue-
resident mast cells. Eosinophils and mast cells are found in close proximity to one another under 
homeostatic conditions in the gut, and they also colocalize in the allergic lung and in the inflamed 
gut in patients  with  Crohn’s  disease. The bidirectional signalling that occurs between eosinophils 
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and mast cells involves several immunomodulatory mediators. These include stem cell factor (also 
known as KIT ligand), granule proteins, cytokines (such as granulocyte–macrophage colony-
stimulating factor (GM-CSF), IL-3, IL-5 and tumour necrosis factor (TNF)), nerve growth factor 
and mast cell proteases. Actual physical coupling of eosinophils and mast cells has been observed 
both in vitro and in vivo, and this interaction prolongs eosinophil survival. 
 
 
Figure 1.3 Eosinophils not only respond to signals, but also have a definitive impact on the actions of other 
leukocytes. Eosinophils can express MHC class II and co-stimulatory molecules, process antigens and 
stimulate T cells to proliferate and produce cytokines in an antigen-specific manner. Furthermore, acting 
together with dendritic cells (DCs), eosinophils regulate the recruitment of T helper 2 (TH2) cells in 
response to allergen sensitization and challenge by producing CC-chemokine ligand 17 (CCL17) and 
CCL22. Eosinophils also prime B cells for antigen-specific IgM production and sustain long-lived plasma 
cells in mouse bone marrow via the production of a proliferation-inducing ligand (APRIL) and interleukin-6 
(IL-6). Eosinophils that are stimulated by CpG DNA induce DC maturation. Major basic protein (MBP) 
released from eosinophils activates neutrophils, causing them to release superoxide and IL-8 and increase 
their expression of the cell-surface integrin complement receptor 3 (CR3). Eosinophils also maintain 
alternatively activated macrophages in adipose tissue by producing IL-4 and IL-13. The eosinophil granule 
proteins MBP, eosinophil cationic protein (ECP) and eosinophil peroxidase (EPX) activate mast cells, 
resulting in the release of histamine. Likewise, eosinophil-derived nerve growth factor (NGF) prolongs mast 
cell survival. 
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- MAST CELLS 
Mast cells are members of the innate immune system that develop from CD34+ hematopoietic 
precursor cells in the bone marrow and circulate in the blood in an immature form. Only after they 
have established residency in a particular tissue, do they complete their tissue-specific 
differentiation and maturation.  
Both the regulation of mast-cell survival and proliferation and the modulation of important 
phenotypical characteristics of mast cells — including their susceptibility to activation by various 
stimuli during innate or adaptive immune responses, their ability to store and/or produce various 
 secreted products, and the magnitude and nature of the secretory response of mast cells to specific 
activation stimuli— can  be  finely  controlled  or  ‘tuned’.  The  main  survival  and  developmental  factor  
for mast cells is stem-cell factor (SCF; also known as KIT ligand), but many growth factors, 
cytokines and chemokines can influence the number and phenotype of mast cells, including 
interleukin‑3 (IL‑ 3), which is of particular importance in mice, TH2-cell-associated cytokines 
(such as IL‑ 4 and IL‑ 9), CXCL12 (also named stromal cell-derived factor-1, or SDF-1) [Lin et 
al., 2000; Godot et al., 2007], nerve growth factor (NGF) and transforming growth factor-β1 (TGF-
β1). 
Mast cells are often classified according to their location or protease content. In mice, MCs can be 
classified into two subpopulations: mucosal type MCs and connective tissue-type MCs [Galli et al., 
1984]. In humans, MCs are subcategorized into MCT, which express high levels of the MC-specific 
protease tryptase but not of chymase, and MCTC, which express both tryptase and chymase. 
 
 
- PHYSIOLOGICAL AND PATHOLOGICAL ROLE  
 
Mast cells are considered first line defenders against infections because of their prevalence in 
tissues such as the skin, gut, respiratory tract and urinary tract that form the barriers between self 
and the environment. They are also found in close association with blood vessels, lymphatic vessels 
and nerves. These anatomical locations license mast cells to contribute to a multitude of protective 
and pathologic events including angiogenesis, wound healing and the exacerbation of inflammation. 
While the numbers and activation of MCs increase in many human diseases, proof of MC 
involvement in these diseases has been derived mostly from animal models developed in various 
strains of MC-deficient mice [Grimbaldeston et al., 2005; Tsai et al., 2005; Reber et al., 
2012; Rodewald and Feyerabend, 2012]. Studies in these animal models suggest that MCs play 
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important roles in a variety of immune and inflammatory reactions, including a central role in 
allergies, defense against some pathogens, resistance to venoms, and development or exacerbation 
of certain autoimmune diseases. Mast cells can also influence many aspects of the biology of 
immune cells, including granulocytes, monocytes/macrophages, dendritic cells (DCs), T cells, B 
cells, natural killer (NK) cells and NKT cells. In this case, the effects of mast cells on the 
recruitment, survival, development, phenotype or function of immune cells are referred to as 
‘immunomodulatory’  functions. 
Through their effector and/or immunomodulatory functions, mast cells can promote the initiation 
and increase the magnitude of inflammation, tissue remodelling and, in some cases, tissue injury 
associated with the innate or adaptive immune response. 
 
- MAST CELLS ACTIVATION 
 
Mast cells are famous for their role in hypersensitivity reactions where they are activated by cross-
linking of the high affinity IgE receptor (FcεRI). 
 Depending on the type, property, strength, and combination of the stimuli they receive, MCs 
secrete a diverse and wide range of biologically active products that can trigger, direct,or suppress 
the immune response. Mast cells soluble products can be divided into two categories: (a) preformed 
mediators, such as histamine, proteoglycans, and neutral proteases and certain cytokines, in 
particular tumor necrosis factor-alpha (TNF-α), that are rapidly and instantaneously released upon 
activation; (b) newly synthesized mediators, such as cytokines, chemokines, lipid mediators, growth 
and angiogenic factors that start to be synthesized after MC activation. Although these products are 
all important in both innate and acquired immunity, the rapid release of mast cells mediators is 
crucial for the initiation of the immune response at the site of infection since they are able to 
modulate the immune-cell trafficking and to provide co-stimulatory signals for cell activation. 
Tissue mast cells are the major resident cell population expressing FcεRI and IgE-antigen cross-
linking results in the release of several preformed molecules that are stored in mast cell granules 
including histamine, serotonin, tryptase, chymase as well as the lipid-derived mediators 
prostaglandin D2 (PGD2) and leukotriene B4 (LTB4). These mediators affect many aspects of the 
early-phase allergic reactions such as vasodilation, local or systemic increases in vascular 
permeability, constriction of smooth muscle and mucus secretion. Such activation also leads to the 
release of newly synthesized mediators, which can initiate more severe and prolonged late-phase 
allergic responses. 
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Figure 1.4 The  mast  cell,   the  “jack  of  all   trades”   immune  cell.  The  multitude  of  activators  and   the  many  
modes of mast cell response account for their ability to impact a variety of physiological and pathogenic 
processes. Receptor-binding agonists, physical activators and cell–cell contact can all activate mast cells.  
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2. INTEGRINS 
Integrins are a major family of cell surface-adhesion receptors that are expressed in all metazoans. 
In   vertebrates,   18   α subunits and 8 β subunits have been discovered, which combine into 24 
different heterodimers that recognize overlapping but distinct sets of extracellular ligands (Figure 
2.1) [Humphries JD et al., 2006; Hynes RO, 2002] . 
 
 
Figure 2.1 Integrin family. Integrins are loosely grouped into three classes that bind basal extracellular 
matrix (ECM), provisional ECM and cell surface adhesion molecules (CAMs), respectively. Basal ECM 
mainly includes fibrinogen, fibronectin, vitronectin, cryptic collagen and von Willebrand factor. 
 
 
As adhesion molecules, integrin can mediate cell-cell, cell-matrix and cell-pathogen interactions 
[Askari JA et al., 2009]. Integrin-mediated adhesion and signaling events are important in normal 
physiological responses including immune response, tissue morphogenesis, wound healing, 
hemostasis, cell survival and cell differentiation. Conversely, dysregulation of integrins are 
involved in the pathogenesis of many diseases, including cancer metastasis, auto-immune disease 
and thrombotic vascular diseases.[Garmy-Susini B. et al., 2008; von Andrian UH et al., 2003]  
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2.1 Integrin Overall Structure  
Integrins thus are able to communicate binding to the extracellular matrix or ligands on other cells 
to the actin cytoskeleton, to discriminate against soluble ligands, and to bind only with high affinity 
to cell surface or matrix-bound ligands [Luo et al., 2007; Springer and Dustin, 2012]. 
Integrins are type I trans-membrane proteins with large ectodomains, short trans-membrane and 
cytoplasmic domains (except for β4 subunit with exceptional long cytoplasmic domain of ~1,000 
amino acids). There are four extracellular domains, β-propeller, thigh, calf-1 and calf-2, present in 
all   α   subunits.   In   addition,   half   of   the   α subunits incorporate an additional autonomous folding 
domain of ~200 amino acids termed the inserted domain (I domain) (Figure 2.2). Thus, integrins 
can  be  classified  into  two  subfamilies,  the  α  I-containing    integrins  and  α  I-less integrins.   
The β subunit ectodomain contains eight domains, β I domain, hybrid, PSI, β-tail and four integrin-
EGF domains. Electron microscopy and X-ray crystal structure studies  of  several  integrins  (αIIbβ3, 
αVβ3, αXβ2) have demonstrated independently that the overall shape of integrin ectodomain is that of 
a   large  “head”  on   two   long  “legs”  with   flexible  “knees”   (Fig.  2.2, panel B and C) [Xie C. et al., 
2010; Xiong JP et al., 2009]. The  α  head  is  composed  of  β-propeller  domain  and  α I  domain  in  α  I-
containing integrins, while a single β-propeller  forms  a  head  in  α  I-less integrins. The β I domain, 
sharing  the  same  overall  fold  as  the  α  I  domain,  is  present  in  all  β subunits and forms β head.  α  I  
domain   is   the   ligand  binding  domain   in  α   I-containing integrins whereas the β I domain forms a 
major ligand binding  pocket  in  α  I-less integrins.  
Integrin affinity regulation is highly related to its global and local conformational rearrangements. It 
has been demonstrated that integrins exist in at least three conformational states: the bent 
conformation with closed headpiece, the extended conformation with closed headpiece and the 
extended conformation with open headpiece, which are corresponding to the low-, intermediate- 
and high-affinity states, respectively  (Fig. 2.2, panel B and C). Correspondingly, it is proposed that 
integrin activation is accompanied with a switchblade-like opening of the headpiece-tailpiece 
interface, which extends the ligand-binding headpiece of the integrin heterodimer away from the 
plasma membrane. 
The α subunit  β–propeller and thigh domains and the β subunit β I, hybrid, PSI (plexin, 
semaphorin, and integrin), and I-EGF-1 domains form the ligand binding headpiece, the head and 
the upper legs. The α subunit calf-1 and calf-2 and the β subunit I-EGF-2 to I-EGF-4 and β tail 
domains form the lower legs [Xiong et al., 2001; Zhu et al., 2008]. 
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Figure 2.2 Schematic representation of integrin structure and conformational rearrangements. Panel A, 
organization  of  domains  within  the  primary  structure.  α  I  domain  inserted  in  β-propeller is denoted by dash 
lines. Yellow and red asterisks denote Ca2+ and Mg2+-binding sites, respectively. Open asterisk denotes the 
Ca2+-binding   site   in   the   forth   repeat   of   β-propeller   domain   in   some   α   subunits.   Panel   B   and   C,  
conformational  rearrangements  of  αI-containing  (B)  and  α  I-less integrins (C) during activation. 
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Two distinct types of global conformational changes occur in integrin extracellular domains. 
Extension at the knees releases integrins from a compact bent conformation (Figure 2.3, A, B, D, 
and E). In integrin headpiece opening, the hybrid domain swings out, the β I domain changes from 
closed to open conformation, and affinity for ligand increases [Luo et al., 2007]. 
β I domains, present in all integrin β subunits, transmit conformational change from their interface 
with the swinging hybrid domain to a ligand binding site at an interface with the α subunit β -
propeller domain (Figure 2.3, A–F). 
The β I domain divides the hybrid domain into N- and C-terminal sequence segments. Activation at 
the metal ion-dependent adhesion site (MIDAS) in the β I domain ligand binding site is 
communicated to the opposite end of the  β I domain by  α7 helix pistoning at the C-terminal 
connection to the hybrid domain. 
 
 
 
Figure 2.3 Integrin domain organization and conformational states. Two lower β   leg   conformations   (one  
with a dashed  line)  are  shown  for  the  extended  states  because  the  lower  β  leg  is  highly  flexible,  and  these  
states  can  exist  with  the  α  and  β  TM  domains  either associated or separated. However, signal transmission 
through the membrane, both in the inside-out and outside-in directions, requires TM and cytoplasmic 
domain separation. 
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2.2 Role of divalent cations in integrin function  
Most integrins are not constitutively active and often expressed on cell surface in an inactive state, 
in which they neither bind ligands nor signal. The basal low adhesiveness of integrins is very 
important for their biological functions, such as integrins on circulating blood cells.  
Cell surface integrins are in the equilibrium among these conformational states which can be shifted 
by certain stimuli, such as extracellular metal ions. Divalent cations are essential for integrin 
functions, from stabilizing integrin structure to mediating its interaction with the ligand and 
modulating integrin-ligand binding in either an enhancing or a suppressing way. The removal of 
divalent cations by EDTA completely inhibits integrin-ligand binding. And the formation of 
integrin heterodimer complex is also dependent on the presence of at least micromole levels of 
divalent cations.  
Physiologically, most integrins are in the resting state with the presence of 1 mM Ca2+ and 1 mM 
Mg2+ in body fluid. The millimole level Ca2+ often has an inhibitory effect on integrin-ligand 
binding [Dransfield et al., 1992; Humphries MJ, 1996]. By removal of Ca2+, the remaining Mg2+ 
alone can promote ligand binding in most integrins. Studies also indicate that micromolar Ca2+ can 
synergize with suboptimal concentration of Mg2+ to further activate integrins. As a non-
physiological stimulus, Mn2+ can shift integrins into high affinity conformations (detected by 
special activation-dependent mAbs) and strikingly activate integrins, even with the presence of 
millimolar Ca2+. 
Three kinds of binding sites for Ca2+ have   been   identified   in   α4β1, which differ in Ca2+-binding 
affinity [Chen et al., 2001]. The first kind is a moderate-affinity site (ED50 50–100 mM) that only 
can be rapidly occupied after integrin binds ligand; the second kind is a ligand binding-independent 
high-affinity site (ED50 20 mM); the third kind has the low-affinity for Ca2+ and its occupancy can 
inhibit integrin-ligand binding. Integrin crystal structures have provided new insights into the metal 
ion-binding sites, and their functions are further revealed by mutagenesis studies. To date, eight 
divalent cation binding sites have been discovered in integrin ectodomains with five in a subunit 
and  three  in  β  subunit.  
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2.3 Integrin signalling 
 
In addition to their structural role, integrins are highly involved in signal transduction processes. 
Integrin  signaling  has  often  been  divided  into  ‘inside-out signaling’  and  ‘outside-in  signaling’.  The  
former refers to the fact that integrins can exist in activated, inactive or intermediate states, in 
response to external cues. The solution of the crystal structure of the external domain of the αvβ3 
integrin [Xiong et al., 2001], followed by further progress on structure and function, has been very 
helpful in understanding integrin activation. Thus, in the inactive state the integrin external domain 
is thought to be in a bent configuration while the cytoplasmic tails are closely juxtaposed by charge-
charge interaction. In the active form the external domain is extended and the tails separate. 
The association of the cytosolic protein talin with the beta subunit tail is the key final step in 
integrin activation [Kim et al., 2011; Margadant et al., 2011]. However, a multiplicity of other 
proteins, particularly the small GTPase Rap1, are involved in the regulation of ‘inside-out 
signaling’. 
 
x TALIN 
 
Talin is a 270 kDa protein which is composed of a 50 kDa N-terminal globular head domain and a 
220 kDa C-terminal rod domain. The talin head domain contains three FERM (protein 4.1, ezrin, 
radixin, moesin) subdomains: F1, F2, and F3, and a non-homologous F0 domain. The PTB 
(Phosphotyrosine Binding) domain is located in the F3 subdomain and binds to the conserved 
membrane-proximal NPxY motif of β integrin cytoplasmic tail, and binding of the F3 domain is 
sufficient to activate integrins [Calderwood et al., 2002]. 
THD has two binding sites in the β integrin cytoplasmic domain. It can bind strongly to NPxY 
motif and weakly to the membrane proximal part of β3 integrin [Wegener et al., 2007]. 
Mutations that interrupt the strong integrin–talin interaction (NPxY-talin interaction) totally 
abolished the ability of talin to activate integrin whereas disrupting the weak talin–integrin 
interaction showed little effect on talin affinity but reduced integrin activation [Tanentzapf and 
Brown, 2006; Wegener et al., 2007]. This interaction is important in precise talin–integrin 
positioning and interrupting the interaction resulted in defected integrin activation [Anthis et al., 
2009]. Binding of talin to the β integrin tail may cause TM domain separation (Fig. X), leading to 
integrin activation [Ye et al., 2011]. An in vitro reconstruction of integrin activation showed that 
binding of  THD alone is sufficient to trigger integrin global extension and activation in lipid 
nanodiscs. 
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The rod domain of talin contains multiple binding sites for actin, vinculin, and an autoinhibitory 
binding site to its own integrin activating THD [Calderwood, 2004; Goksoy et al., 2008; Moser et 
al., 2009]. 
The C-terminal rod of talin also has essential role in integrin signaling. Over expression of THD 
cannot restore integrin clustering and focal adhesion formation in talin depleted cells and a more 
recent research implicated a potential role of talin rod domain in cell proliferation regulation, 
indicating the importance of this domain in integrin outside-in signaling [Zhang et al., 2008; Wang 
et al., 2011]. 
 
 
 
 
Figure 2.4  Talin and integrin signaling. A, in  resting  state,  TM  domains  of  α  (red)  and  β  (blue)  subunits are 
associated together. B, talin  binding  to  β  integrin  cytoplasmic  tail  NPxY motif and membrane proximal part 
causes  change  of  β  integrin  TM  domain  tilt  angle  (from  gray  to  blue)  resulting  in  longer  helix  embedment  
and induces TM domain separation. C, talin  displacement   from  β  cytoplasmic   tail   in  outside-in signaling. 
Phosphorylation on the tyrosine residue (red sphere) of NPxY motif decreases talin binding affinity, resulting 
in  displacement  of  the  protein  by  other  β  integrin-binding proteins. 
 
 
x KINDLIN 
 
Another integrin binding protein kindlin also plays a critical role in integrin activation. The kindlin 
family is consisted of three members: kindlin1, kindlin2, and kindlin3. Kindlins are well conserved 
in animals and defects on family members can cause serious diseases. 
Kindlins have three C-terminal FERM domains, similar to talin, but the F2 domain is split by an 
inserted Pleckstrin Homology domain. While talin strongly binds to membrane proximal region of 
the β integrin cytoplasmic domain, kindlin F3 domain interacts with the membrane distal NxxY 
motif [Moser et al., 2008; Harburger et al., 2009]. 
                                                                                                                                                             Chapter 2- Integrins 
22 
 
2.4 Outside-In Signaling  
 
In physiological conditions, only a fraction of integrins on the cell surface may adopt an extended 
conformation with high affinity for ligands. However, exposure to extracellular matrix (ECM) 
ligands results in stabilizing of high affinity state and integrin clustering, which in turn increases 
ligand binding valency or avidity. Clustered integrins not only provide stable connections to ECM 
but also transfer extracellular information into corresponding intracellular reactions by recruiting 
effectors to integrin cytoplasmic tail. This outside-in signaling of integrin regulates cell shape, 
migration, growth, and survival. It has been shown that both lateral association (clustering) of 
integrin heterodimers and the conformational change of the receptors are required for conveying 
outside-in signals [Luo et al., 2007; Zhu et al., 2007; Wang et al., 2010, 2011b). 
Integrin engagement with ECM can also modulate the classic Erk/MAP Kinase pathway 
downstream from RTK activation [Juliano et al., 2004]. This involves regulation at the level of the 
Raf-1 kinase [Edin and Juliano, 2005; Lin et al., 1997] and also effects on the trafficking of 
activated Erk to the nucleus [Aplin et al., 2001]. 
Integrins can also signal directly via activation of tyrosine kinases. The discovery that cell adhesion 
or integrin clustering could activate tyrosine phosphorylation via focal adhesion kinase (FAK) was 
a key event in understanding the function of integrins [Kornberg et al., 1991; Schaller et al., 1992]. 
FAK recruitment to integrin cytoplasmic tail is an early event in outside-in signaling [Parsons, 
2003; Schlaepfer and Mitra, 2004]. This non-receptor tyrosine kinase is highly conserved and FAK 
knock-out is embryonic lethal in mice. FAK is consisted of an N-terminal FERM domain which 
functions as an activation switch and adaptor, a central catalytic domain, a proline-rich region and a 
C-terminal FAK Adhesion Targeting domain. Under resting state, the FERM domain interacts with 
its own catalytic domain and therefore blocks accessibility of FAK substrates [Cooper et al., 2003; 
Dunty et al., 2004; Lietha et al., 2007]. Early evidence indicated that interaction between the FAK 
FERM domain and β integrin tail releases this autoinhibition, causing FAK autophosphorylation 
and activation [Schaller et al., 1995]. Displacement of the FERM domain from its catalytic domain 
results in autophosphorylation on tyrosine 397, which leads to Src activation. Then activated Src 
further phosphorylates and promotes FAK activity. FAK activation is closely associated with focal 
adhesion formation and cell migration.  
Recruitment of Src leads to additional tyrosine phosphorylations with several consequences 
including recruitment of the SH2-adaptor Grb2 in complex with SOS,a GEF for Ras, leading to 
activation of the Ras-MAP Kinase cascade. Further, SH3 domains mediate binding of GRAF and 
ASAP1, which are GAPs for the Rho and Arf 1/6 small GTPases, leading to effects on the actin 
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cytoskeleton. Additionally the adaptor protein Cas and its partner Crk recruit the DOCK180/ELMO 
complex which acts as a GEF for the Rac GTPase and thus to further effects on the cytoskeleton. 
Finally, the adaptor protein paxilin binds to a sequence in the c-terminal of FAK and serves both as 
a structural protein linking to actin and also influence the ERK pathway via Raf-1.  
Thus FAK serves as the hub of a multi-protein signal transduction complex that influences cell 
cycle, cytoskeletal organization, and cell motility. 
 
 
 
 
 
 
Figure 2.5 Signaling by Integrins, RTKs and GPCRs. This illustrates highly simplified versions of the 
downstream signaling pathways regulated by these three families of receptors as well as some of the 
interconnections between pathways. Cytoskeletal proteins-Talin, Vinculin (Vinc), Paxilin (Pax); Adaptor 
proteins-Grb2, Cas, Crk, Pkl, Pix, beta-arrestin (βA); Small GTPases-Ras, Rac, Rho; Heterotrimeric 
GTPase (Gα/βγ) Tyrosine kinases-Focal Adhesion Kinase (FAK), c-Src, RTK; Serinethreonine kinases-PAK, 
Raf-1, MEK (dual specificity), Erk, Grk; Guanine nucleotide exchange factors-SOS,DOCK180/ELMO; 
Metalloprotease (MP). 
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3. THE LEUCOCYTE RECRUITMENT CASCADE IN INFLAMMATION 
 
The circulation of leukocytes including lymphocytes, monocytes, macrophages, dendritic cells, and 
granulocytes from the peripheral circulation (blood pool) to other tissues including the gut mucosa 
is an important aspect of immune surveillance [Delves and Roitt, 2000b; Delves and Roitt, 2000a; 
McIntyre et al., 2003]. A crucial feature of any inflammatory response is a rapid recruitment of 
leukocytes from the blood to the site of inflammation. 
Leucocyte recruitment not only plays a role in the acute response to pathogen infection or tissue 
injury but also represents a major pathophysiological component of almost any inflammatory 
pathology, including atherosclerotic vascular disease, or autoimmune diseases, such as rheumatoid 
arthritis, psoriasis or multiple sclerosis. 
Leukocyte recruitment into inflamed tissue follows a well defined cascade of events, beginning with 
capturing of free flowing leukocytes to the vessel wall, followed by rolling, adhesion to endothelial 
cells, postadhesion strengthening, crawling, and finally transmigration (Figure 3.1). During these 
steps, different integrins have to be activated via inside–out signaling. Each step necessitates a 
different set of integrins that differs among leukocyte subsets. Similarly, different activating stimuli 
trigger distinct signaling pathways during every step.  
Leukocyte expressed integrins include the α4 integrins (CD49d),  α4β1 (VLA4) and α4β7 (LPAM) 
and the β2 integrins αLβ2 (LFA-1, lymphocyte function-associated antigen-1, CD11a/CD18) and 
αMβ2 (Mac-1, macrophage antigen-1, CD11b/CD18). 
Besides mediating firm leukocyte arrest, α4β1 which binds to VCAM-1 (vascular cell adhesion 
molecule-1), and α4β7, interacting with VCAM-1 and MAdCAM-1, are able to mediate leukocyte 
rolling independent of selectins. The endothelial counter-ligands of leucocyte integrins also include 
several receptors of the immunoglobulin superfamily, such as the intercellular adhesion molecules 
(ICAM)-1-5, whereby the most studies exist on ICAM-1 and ICAM-2. Both ICAM-1 and ICAM-2 
can specifically bind to LFA-1 and Mac-1. 
 
Capturing and rolling. Capturing of leukocytes from the bloodstream is initially mediated by 
selectins displayed on the endothelial luminal surface and their corresponding counter-receptors on 
leukocytes. This initial contact triggers a signaling cascade leading to the activation of integrins on 
the rolling leukocyte to an intermediate-affinity conformation effectively slowing down the rolling 
velocity of the   cells   (hence   the   term   “slow   rolling”)   [Kuwano   et   al,   2010;;   McEver et al., 
2010].Integrin activation in leukocyte rolling is best understood in neutrophils rolling on E-selectin. 
The importance of integrins in monocyte and T cell rolling is less well studied. In vitro studies 
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suggest a predominant role of VLA-4 for monocyte rolling, as blockade of b2-integrins by mAbs 
had no effect on rolling flux and cell adhesion on IL-4–activated HUVECs [Luscinskas et al., 
1994]. CD4+ T cells were also found to roll on P- and E-selectin [Alon et al., 1994]. CD8+ T cells 
roll on TNF-a– and IFN-g–treated vessels in a VLA-4–dependent manner. VLA-4 seems to be the 
predominant integrin mediating lymphocyte rolling [Nandi et al., 2004]; however, physiological 
relevance of monocyte and T cell rolling for recruitment to peripheral tissues and involved signaling 
pathways affecting integrin affinity and avidity are still unclear. 
Adhesion and postadhesion strengthening. In most tissues rolling or tethering is insufficient to 
permanently target the leukocyte to the vessel wall: without further stimuli the cell detaches. During 
rolling, however, leukocytes pick up inflammatory signals presented on the endothelial cells that 
may trigger arrest. On a cellular level, leukocyte arrest is mediated by the activation of GPCRs that 
mediate activation of integrins to their extended, high-affinity conformation, resulting in binding of 
ligands such as ICAM-1 or VCAM-1 [Ghandour et al., 2007]. Lateral movement of integrins on the 
cell surface following arrest results in an accumulation of integrins at the site of endothelial ligand 
presentation, forming   an   integrin   “cluster”   at   the leukocyte/endothelial border. This increase in 
avidity may represent a trigger event for outside–in signaling, thus marking a crucial event for 
postadhesion strengthening. VLA-4 and LFA-1 seem to be the predominant integrins mediating T 
cell adhesion, whereas monocytes adhere in a VLA-4– or   β2-integrin–dependent manner and 
neutrophil adhesion is LFA-1 dependent. 
Intravascular crawling. Crawling was first observed in vitro and initially   termed   “locomotion”:  
monocytes that adhered to HUVECs were found to actively move to cellular junctions to start 
transmigration within seconds. However, the molecular events involved in the transition from 
adhesion to crawling are still largely elusive. 
Transmigration and detachment. At the preferred site of transmigration, integrin binding to ICAM-
1 and VCAM-1 constitutes central players in the orchestra of protein interactions involved in both 
para- and transcellular transmigration [Williams et al., 2007]. Activated endothelium forms ring-
like membrane structures enriched with ICAM-1 and VCAM-1 that are maintained for the duration 
of transmigration. 
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Figure 3.1. A, Integrins in leukocyte recruitment. In each step of the leukocyte recruitment cascade, 
integrins play a crucial role. During rolling, integrins mediate interaction with the endothelium. After this 
contact, integrin activation mediates cell arrest, and accumulation of integrins at the endothelial/leukocyte 
bordermarks postadhesion strengthening. Leukocytes then crawl over the endothelium before they 
transmigrate and finally detach. Integrins found to be involved in each step are listed below. 
 
 
3.1 ASPECTS OF VLA4 FUNCTION AND REGULATION 
According to the UniGene EST profile the overall expression patterns of integrin alpha 4 subunit 
(ITGA4) and integrin alpha L subunit (ITGAL) are very similar. These integrins are expressed in 
tissues associated with blood and lymphatic tissues. Blood, bone marrow, lymph, lymph nodes, 
spleen, and thymus are primary sites of expression. However, VLA-4 integrin is strongly expressed 
on CD34+ early hematopoietic stem progenitor cells (HSPCs). Its expression is critical for homing 
and retention of HSPCs, since blocking VLA-4-specific interactions using mAbs or small molecule 
antagonists is sufficient to induce cell mobilization into peripheral blood [Coulombel et al., 1997; 
Oostendorp and Dormer, 1997; Gazitt, 2004; Chigaev et al., 2011d]. This observation is also 
confirmed by the fact that the expression of VLA-4 is more pronounced  in  “germ  cell  tumors.” 
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First, it directly participates in cell arrest under flow, where firm adhesion is mediated by activated 
(high-affinity, unbent) integrins. Second, VLA-4 contributes to cell-cell interactions that are critical 
for immune system responses. For example, it plays a part in the formation of immunological 
synapse, and participate in cell co-stimulation. 
The discovery that in addition to firm adhesion, VLA-4 can mediate cell tethering and rolling [Alon 
et al., 1995] represents the first indication of a functional difference between VLA-4 and LFA-1. 
More detailed analysis revealed that VLA-4 supports a number of adhesive interactions that are 
directly related but not limited to the maintenance of immune cells through hematopoiesis [Imai et 
al., 2010], as well as intrinsic immune responses. Thus, VLA-4 participates in chemokine- 
dependent cell arrest on endothelium, NK, and MKT cell recruitment to bone marrow, cell 
recruitment in response to bacterial infections, bacterial killing. 
 
3.2 CONFORMATIONAL ANALYSIS OF INTEGRIN VLA-4 STATES 
Taken together, the overall scheme of the VLA-4 conformation regulation can be generalized as 
follows (Figure 3.2). At rest, the low affinity bent conformation prevents cell tethering and rolling 
because of the positioning of the ligand binding site. If ligand engagement occurs, it would have a 
very short lifetime. However, it is also possible that a series of engagements of integrins or other 
receptors [selectins for example [Kuwano et al., 2010] could provide a signal resulting in molecular 
extension. 
This could lead to rolling on an extended low affinity integrin. Rapid activation by Gαi-coupled 
GPCR induces a short-lived high affinity extended state (seconds to minutes), followed by a 
sustained extended low affinity state. If during the short period that VLA-4 engages its counter-
structure, a long-lived tether will form. Under shear and external force this interaction can 
potentially be sustained for a longer period of time because of mechanical (catch bond) or 
signaling/cytoskeletal events. If no engagement of the integrin occurred, a low affinity extended 
state could be ideally suited for rolling under shear. 
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Figure 3.2 Model of VLA-4 integrin conformation and affinity. The bent low affinity state is observed on 
resting cells (I). Activation by phorbol ester creates a high affinity state lacking molecular extension as 
detected by a FRET-based approach (II). This conformation results in the slow accumulation of cell 
aggregates in suspension, with a low tether capture frequency but a long tether duration in the rolling assay. 
The addition of VLA-4 specific ligand to resting cells leads to exposure of a hybrid domain (LIBS) epitope 
(III). This state is bent (or at least not fully extended) because a further molecular extension can be detected 
with a FRET-based approach. Activation   through   a  wild   type  Gαi-coupled GPCR induces a high affinity 
extended conformation (IV). This conformation results in the rapid accumulation of cell aggregates in 
suspension , with high tether capture frequency and long tether duration. The low affinity extended (or at 
least partially extended) conformation (V) can be detected for several minutes after signaling from wild type 
Gαi-coupled GPCR, because of relatively faster desensitization of the ligand binding affinity than relaxation 
of  the  conformation.  Conformation  V  may  also  result  from  consecutive  stimulation  through  Gαi-coupled and 
Gαs-coupled receptors .The ligand occupied and extended high  affinity   state   (VI)  was  detected  after  Gαi-
coupled GPCR activation in the presence of ligand. 
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3.3 INTEGRIN PHYSIOLOGY AND ITS IMPLICATION FOR DRUG 
DISCOVERY 
Natural ligands of VLA4 are, for example, the vascular cell adhesion molecule-1 (VCAM-1) and 
fibronectin with its alternatively spliced connecting segment CS-1 domain as binding motif. 
Fibronectin is recognized by VLA4 via the Leu-Asp-Val (LDV) binding epitope and VCAM-1 
interacts via QIDSPL recognition sequence. Integrin   α4β1 is mainly expressed on the surface of 
lymphocytes, eosinophils, monocytes, basophils, and mast cells, whereas α4β1 is present on 
subpopolations of T- and B-lymphocytes and on eosinophils. 
Diseases associated with α4β1 and α4β7 are mainly inflammatory and autoimmune diseases which go 
along with a pathological accumulation of activated leucocytes in the affected tissues [inflammatory 
bowel disease (IBD), rheumatoid arthritis   (RA),  asthma,  Crohn’s  disease   (CD),  multiple   sclerosis  
(MS)]. Their involvement in disease processes prompted several pharmaceutical companies to 
pursue  α4 integrin antagonists as potential anti-inﬂammatory  agents. 
Natalizumab (Elan and Biogen, Inc.) was the first humanized monoclonal  antibody  targeting  the  α4-
integrin subunit. And was approved by the FDA for the treatment of MS and CD in 2004. The 
application of the drug caused severe side effects in three patients resulting in an infection with 
PML, but a re-evaluation of the FDA brought it back to the market in 2008 under the trade name of 
Tysabri for patients with moderate to severe CD after an inadequate response to conventional 
therapies and patients suffering from a severe form of MS with lack of alternative therapies. 
Natalizumab recognizes an α4 region with significant sequence variation among human and 
mammals commonly used in disease models and toxicology (Figure 3.3). By contrast, the long 
narrow binding groove for small molecule antagonists and the biological ligands MAdCAM and 
VCAM is highly conserved in α4β7 and invariant in α4β1 (Figure 3.3). Domain 1 of VCAM can be 
docked in this groove with some precision by placing the Asp side chain of its rigid, integrin-
binding  loop  in  the  same  β I domain MIDAS Mg2+-coordinating position as the carboxyl group of a 
co-crystallized antagonist.  
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Figure 3.3 Species-specific  differences  around  the  integrin  α4β1  ligand-binding sites. Conservation on the 
solvent accessible surface is displayed from invariant (1, green or blue) to low (0.1, red) for both panel using 
the species shown in bottom. Mouse-human sequence is shown as invariant (green or blue) or different (red). 
Invariant   α   and   β   subunit   residues   are   shown   in   green   and   blue,   respectively,   to   visualize   the   subunit  
interface. Additionally, invariant VCAM-binding   α4   residues   Tyr-187 and Trp-188 are in yellow   and   β  
subunit MIDAS and ADMIDAS metal ions are shown as green spheres. Antibody footprints are outlined in 
yellow dashes (N for natalizumab) and key antigenic residues are labeled. VCAM is shown in ribbon 
representation in the orientation found previously in docking to α4β7. The α4β1 model was made by 
superimposing   the  β1βI  domain   from  α5β1 onto α4β7. The location of the ligand binding groove is marked 
with dashed lines. Sequence conservation was calculated by AL2CO  with species equally weighted, using the 
sum of pairs measure with the BLOSUM62 matrix with normalization of the scoring matrix. The bottom 
panel represents sequence variation in the natalizumab epitope. Sequences are of species found to be 
positive (+) or negative (-) for natalizumab reactivity in European Medicines Agency filings. Residues in the 
epitope are numbered. Residues most important for species reactivity are in bold. Residues that differ from 
human are red. 
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The orientation between D1 and D2 of VCAM-1 is variable among crystal structures (Figure 3.4). 
D1 of docked VCAM does not clash with natalizumab Fab; however, where D2 of VCAM emerges 
from the groove, it clashes in some orientations (Figure 3.4, panel A and B). This docking model 
thus predicts a noncompetitive mechanism of antagonism where natalizumab would lower affinity 
of α4β1 by limiting the number of VCAM conformations accessible for binding (Figure 3.4, panel 
B). 
 
 
Figure 3.4 Model of VCAM binding to a natalizumab Fab-α4β1 complex. Transparent solvent accessible 
surfaces are shown of the α4 β-propeller domain (wheat), β1βI domain (light blue), and natalizumab Fab 
(gray). Two examples of VCAM D1D2 crystal structures that differ the most in D1-D2 orientation are shown 
in ribbon representation.  
 
The noncompetitive inhibition mechanism described is a departure from previous concepts on how 
antibodies block function, particularly for integrins, which are known to undergo conformational 
change. Natalizumab clearly binds to a different site on α4β1 than VCAM, making the 
noncompetitive mechanism conceptually easy to appreciate. A change in the conformational space 
accessible to D2 of VCAM that is imposed by natalizumab is the simplest explanation of the 
structural and ligand competition data. 
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Because ligand-binding sites are well conserved across species, the finding here that a function-
blocking, species specific antibody binds beside, rather than in, a ligand-binding site may be more 
common than not. Another species-specific therapeutic antibody, vedolizumab, also binds to the 
edge of the ligand-binding   site,   but   on   the   opposite,   β7 side. Vedolizumab inhibits binding of 
MAdCAM,  but  not  VCAM,  to  integrin  α4β7. This unexpected result appears to be a consequence of 
binding close enough to the ligand-binding site to inhibit binding of MAdCAM, but not quite close 
enough to inhibit binding of VCAM. Similarly, efalizumab to LFA-1  binds   to   the  αL βI domain 
outside the binding site for D1 of ICAM-1, in a position where it would clash with or require 
bending away of D2 of ICAM-1. The greater presence of species-specific differences outside of the 
ligand-binding site has thus skewed the current generation of therapeutic antibodies toward 
previously unanticipated mechanisms of action, which include noncompetitive antagonism and 
inhibition of binding of some and not other ligands. Currently, technology is maturing to generate 
synthetic antibody libraries that are devoid of tolerance to self. 
The severe side effect is blamed to the immunosuppressive action of the antibody and is a 
prominent side effect  observed  with  many  α4 antagonist since this leukocyte cell adhesion receptor 
is directly involved in immune response.  
x Peptidic and Non-Peptidic Ligands 
A great variety of small peptidic and non-peptidic ligands interfering with the VCAM-1/VLA-4 
interactions have been extensively described in the literature. For instance, the combination of a 
LDVP sequence and N-terminal o-methylphenylureaphenylacetyl group (MPUPA) leads to the 
potent selective BIO1211. However, residual peptidic nature of this molecule and its related 
compounds resulted in rapid enzymatic hydrolysis and clearance in vivo. Linear and cyclic peptide 
derivatives are predominantly based on the LDV-binding motif, whereas privileged scaffolds for 
small-molecule antagonists are phenylureido-LDV-peptidomimetics (relatively selective for α4β1) 
and acylphenylalanine derivatives (biselective for α4β1 and α4β7). The most advanced small-
molecule drug candidate targeting alpha4 is the orally bioavailable AJM-300 (Ajinomoto) wich is 
currently in clinical Phase III for the treatment of IBD, UC, and CD. 
The small molecule HMR-1031 (Aventis Pharmaceuticals) is currently in Phase II trials for arthritis 
and was formerly investigated for the treatment of asthma. HMR-1031 was investigated together 
with IVL984 and IVL745 in a systematic teratogenicity study and showed that the teratogenic risk 
is corresponding to the affinity of the ligand for the inactivated integrin state. It was observed that 
ligands binding both the activated and inactivated integrins with high affinity showed a significantly 
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higher risk of toxicity and embryonic defects in a whole rat embryo culture when compared to 
compounds binding only to the activated state. The  α4-subtype targeting α4β1 and α4β7 ligands TRK-
170 (Toray Industries: CD) and Firategrast (GlaxoSmithKline/Tanabe: IBD, MS, RA, asthma, CD) 
are currently actively developed in clinical Phase II, all showing good safety profiles and promising 
data in preclinical animal models. 
A majority of compounds specific for VLA-4 and several other integrins, including  αIIbβ3 and  αvβ3, 
are competitive (direct) inhibitors (formally agonists that promote LIBS). Until recently, no VLA-4-
specific allosteric antagonists had been described [Chigaev et al., 2011d]. For a competitive drug, 
the ligand binding site location is very close (or overlaps) with its natural ligand binding site. 
Therefore, direct competition with the integrin natural ligand can be observed. 
For integrins possessing a ligand binding site that is exposed at rest (such as VLA-4), binding of 
competitive inhibitors would occur at any time, and binding site occupancy would simply depend 
on binding affinity and drug concentration. Is it possible to identify allosteric antagonists for 
integrins with an exposed ligand binding site? Using an approach that relies upon the exposure of 
the Ligand Induced Binding Site epitope (LIBS) to distinguish VLA-4 competitive antagonists 
[Njus et al., 2009], several VLA-4-specific allosteric antagonists were identified [Chigaev et al., 
2011d]. These molecules, although not competing directly with VLA-4-specific ligands, blocked 
VLA-4-dependent cell adhesion.  
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4. AIM OF THE RESEARCH 
Inflammation is a key pathophysiological process in a large number of common diseases. The 
motility of its cellular components is a key feature of the immune system since it allows the 
selective recruitment of cells to defined places and niches not only to combat invading pathogens 
but also to pass through tightly controlled programs of immune cell development and maturation. 
The selective recruitment of a particular T cell subset into tissues during inflammation is now 
understood to be a tightly orchestrated multistep adhesion cascade, regulated by selectins, integrins, 
chemokines, and chemoattractant lipids, that specifically directs the trafficking of leukocytes into 
sites essential for their function. It depends on the type of inflammatory response and involves 
interactions between specific ligands expressed on the T cell surface (selectin ligands and integrins) 
with their respective adhesion molecules expressed on the vascular endothelium (selectins and 
intercellular and vascular adhesion molecules ICAM-1/ICAM-2 and VCAM-1) in combination with 
appropriate chemokines. 
When   activated,   α4-family integrins mediate cell–cell adhesions crucial to immune function 
[Kinashi, T., 2012]. α4β1 (VLA-4) binds to fibronectin splice variants at the CS-1 domain, and to 
vascular cell adhesion protein 1 (VCAM-1) which is expressed on activated endothelial near sites of 
inflammation, whereas α4β7 binds to mucosal vascular addressin cell adhesion molecule 1 (MAd-
CAM) to capture antigen-presenting cells in post-capillary venules of peripheral lymphoid tissue 
[Villablanca, E.J. et al., 2011]. 
α4-family integrins have been extensively targeted by drugs selective for one or both receptors. The 
inappropriate activation of leukocytes in tissues by cytokines drives many autoimmune diseases, 
including   multiple   sclerosis   (MS),   Crohn’s   disease,   and   inflammatory   bowel   disease (IBD). 
Targeting integrin α4β1 for pharmacologic blockade may allow for the selected modulation or 
inhibition of the migration of immune cells that traffic to an affected organ and cause disease. 
Despite some obstacles, this idea is quickly becoming reality as an array of drugs that inhibit or 
modulate cell migration are actively being studied in clinical trials. The humanized monoclonal 
antibody   Natalizumab,   which   recognizes   α4   integrins   expressed   on   the   surfaces   of   certain  
lymphocytes, is an effective therapy for multiple sclerosis   (MS)   and   Crohn’s   disease   (CD). 
Natalizumab blocks binding of α4β1 integrin to vascular cell adhesion molecule 1 (VCAM-1), which 
is expressed on endothelial cells in nervous tissue undergoing multiple sclerosis flare. Natalizumab 
also blocks binding of α4β7 integrin to mucosal addressin cell adhesion molecule 1 (MadCAM-1), 
which is up-regulated on endothelial cells in the gut, in patients with active CD. 
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Such an improved understanding of the underlying mechanisms involved, has resulted in the 
identification of an array of potential drug targets aimed at modulating cell migration in order to 
treat a broad range of autoimmune and inflammatory diseases. Small molecules of different nature, 
peptidic, non peptidic and  peptidomimetic, that   inhibit   binding   between   α4   integrins   and   their  
ligands have been the subject of much research in recent years [Dattoli et al., 2013] 
Based on these promises, we analyzed a library of peptidomimetic inhibitors of α4β1 integrin 
constituted by a  rigid  central  scaffold,  β-amino acid residues, and partially modified retro-inverso 
sequence. To determine inhibitory activity of these compounds, first screening were performed in 
vitro through cell adhesion assays in Jurkat E6.1 cells and a binding radioligand assay (SPA). Both 
methods were optimized and set up by us. Scintillation proximity assay (SPA) is a homogeneous 
assay technology which is bead based and removes the need for a filtration step to separate bound 
from free ligand in a receptor binding assay. SPA is routinely used for radioligand binding assays, 
particularly in drug screening applications where high throughput is required. After this first step, 
further analysis concentrated on the most potent compound of the library, named DS70. The overall 
project was developed on two principal branches, defined by  in vitro and in vivo assays.  
We aimed to characterize in vitro its inhibitory activity against α4β1  integrin expressed in different 
cell lines, representatives of all key typologies of cells recruited in an inflammatory process: 
leucocytes, eosinophils and mast cells. This goal was achieved by cell adhesion assays. We also 
confirmed   its   specificity   for   α4 family integrin, employing several cell lines expressing different 
subtypes of integrin receptors.  
Outside-in signaling mediated by natural ligands of extracellular matrix also involves the activation 
of kinases in response to integrin-mediated cell adhesion. Therefore, the combination of lateral 
aggregation of integrins in the membrane and integrin ligand binding leads to recruitment and 
activation of FAK (focal adhesion kinase). This process is not entirely understood, but a 
conformational change leading to FERM domain displacement in FAK is involved. This change is 
associated with increased phosphorylation of tyrosine (Tyr)397, which along with an exposed PxxP 
motif forms a binding site for the Src homology 2 (SH2) and SH3 domains, respectively, of the Src 
kinase. Src then phosphorylates other tyrosines contributing to full activation of FAK. This active 
FAK/Src complex mediates a number of important signaling cascades downstream of integrins. Key 
examples include the control of the ERK MAP kinase pathway, the phosphatidylinositol-3 kinase 
(PI3K)/AKT pathway, and Rho GTPase activities. Therefore, we focused our attention on the 
possibility to modulate levels of FAK and ERK1/2 phosphorylation using different concentration of 
DS70. We definitively tempted to analyze antagonist effects on integrin α4β1 signaling pathways.
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Another mechanism we planned to explore is the possible involvement of integrin α4β1 and the 
consequent effects of its blockade during activation of mast cells, triggered by activated T cells or 
calcium ionophores (PMA and calcimycin). 
According to the literature, it is known that the classical view of mast cells as mere cellular 
effectors of type 2 adaptive immune responses is overcame, arguing in favor of a broader role for 
mast cells including their interaction with different subsets of cells. If it is well established that mast 
cells modulate T-cell responses, it is also known that helper T-cell-derived factors affect mast cell 
biology.  
Th cells have been reported to influence mast cell activation. It has been shown that mouse T cells 
(activated either by PMA or by anti-CD3 antibodies) enhance FcεRI mediated degranulation in 
mast cells [Inamura N., et al., 1998]. This effect is contact dependent and is mediated at least in part 
by LFA1/ICAM-1 interaction. Similarly, human Jurkat T cells triggered by anti-CD3 antibodies 
stimulate HMC 1.1 cells to secrete β-hexosaminidase, TNFα and matrix metalloproteinase.  
Thus, direct contact between surface molecules on mast cells and on activated T cells was found to 
provide the stimulatory signal in mast cells necessary for degranulation and cytokine release 
independent of T cell intracellular function. Indeed, separation of the two cell populations by a 
semi-permeable porous membrane prevented this pathway of mast cell activation [Bhattacharyya 
S.P. et al., 1998]. Finally, morphological analysis of inflamed tissues has often provided data 
compatible with the existence of functional cross-talks between these two cell subsets. For instance, 
mast cells and T cells have been shown in close proximity in human tonsils and in a mouse model 
of contact hypersensitivity [Nakae S. et al., 2005].  
 
With regards to in vivo assays, we chose a classical model of ocular  inflammation, represented by 
the already validated allergen challenge-model closely mimicking allergic conjunctivitis, guinea 
pigs pre-immunized through peritoneal administration of ovalbumin. From previous studies in our 
laboratory [Qasem A.R. et al., 2008], it was known that in a model of allergic conjunctivitis, 
levocabastine eye drops reduced the clinical aspects of the late-phase reaction and the conjunctival 
expression of α4β1 integrin by reducing infiltrated eosinophils.  We also propose that blockade of 
integrin-mediated cell adhesion might be a target of the antiallergic action of DS70 and may play a 
role in preventing eosinophil adhesion and infiltration in allergic conjunctivitis. To further 
characterize its mechanism of action, we evaluated at different times several parameters of 
inflammation assessed in conjunctival samples and in tears, after pre-treatment with compound DS 
70 0.1% (30 and 10 minutes before allergen challenge): clinical score resolution, conjunctival 
eosinophilic infiltration in tears and in conjunctiva, conjunctival mRNA levels of CCL5, CCL11, 
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interleukin (IL)-1E and interleukin-8. We also performed immunohistochemical staining to detect 
changes in expression   levels   of   α4 subunit, and Giemsa staining to observe effects on mast cell 
degranulation. 
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5. MATERIALS AND METHODS 
5.1 IN VITRO EXPERIMENTS 
 
5.1.1 Materials 
Cell culture media, phosphate-buffered saline (PBS) and fetal bovine serum (FBS) were from Lonza 
(Euroclone S.p.A, Milan, Italy); HBSS and chloromethylfluorescein diacetate (CMFDA) were from 
Invitrogen (Carlsbad, CA, USA). Lectin from Triticus vulgaris, soluble fibronectin (FN) from 
human plasma were purchased from Sigma-Aldrich (Steinheim, Germany).  
Black and white 96-well clear-bottom plates were purchased from Corning Costar (Celbio, Milan, 
Italy). Soluble human VCAM-1 and MAdCAM-1 was purchased from R&D Systems (Minneapolis, 
MN, USA). BIO-1211(N-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]-phenyl]acetyl]-L-leucyl-
L-aspartyl-L-valyl-L-proline) was purchased from Bachem (Weil am Rhein, Germany). Tissue 
Protein Extraction Reagent (T-PER) was purchased from Pierce (Rockford, IL, USA).  
Rabbit anti-human monoclonal antibodies against the α4 subunit of α4E1 integrin was purchased 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Mouse anti-human monoclonal 
antibody  against  β1 subunit (MAB 2000) was obtained from Chemicon (Millipore, Billerica, MA, 
USA). Secondary antibody (goat anti-mouse or goat anti-rabbit) were purchased from Santa Cruz 
Biotechnology Inc. Polyacrylamide gel, N,N,N0,N0-tetramethy-lethylenediamine (TEMED), 
ammonium persulfate (APS) and SDS were purchased from Sigma-Aldrich. Hybond-ECL 
Nitrocellulose Membrane was from Amersham Biosciences (GE Healthcare Europe, Milan, Italy). 
Na125I was obtained from PerkinElmer Inc., Waltham, Massachussets, USA). Polyvinyltoluene 
(PVT) anti-rabbit binding beads were supplied by Amersham Biosciences as a powder and 
reconstituted in distilled water. 
 All other reagents were of analytical grade or the highest purity available, purchased from Sigma. 
 
5.1.2 Cell culture 
D283 human medulloblastoma cells originally obtained from the American Type Culture Collection 
(Rockville, MD, USA) were kindly donated by professor Giovanna Cenacchi (Department of 
Biomedical  and  Neuromotor  Sciences,  “Alma  Mater”  University of Bologna). 
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The cells were grown and maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, 
Carlsbad, USA) containing L-glutamine, added with 20 % (v/v) fetal bovine serum (FBS, Hyclone), 
1% non-essential aminoacids (Gibco) and  a mixture of antibiotics and antimycotics 100x (100 units 
of penicillin, 100 µg of streptomycin, 0,25 µg of amphotericin B/ml medium plus 0,85% of 
Fungizone®) (Gibco).  
SK-MEL-24 is one of a series of melanoma cell lines established from patient-derived tumor 
samples. This cell line expresses wild type B-Raf and wild type N-Ras. This cell line was 
established from a metastatic site (lymph node) in a 67-year-old Caucasian male with malignant 
melanoma. SK-MEL-24 cells (ATCC) were routinely grown in minimum essential medium 
(EMEM, Lonza) supplemented with 10% fetal bovine serum (FBS), non-essential aminoacids, 
sodium pyruvate and and a mixture of antibiotics and antimycotics. 
The cell line K-562 (ECACC) was established from the pleural effusion of a 53-year-old female 
with chronic myelogenous leukemia in terminal blast crises. The cell population has been 
characterized as highly undifferentiated and of the granulocytic series. Studies conducted by 
Anderson, et al., on the surface membrane properties led to the conclusion that the K-562 was a 
human erythroleukemia line. K-562 blasts are multipotential, hematopoietic malignant cells that 
spontaneously differentiate into recognizable progenitors of the erythrocytic, granulocytic and 
monocytic series. 
Jurkat cells E6.1 (ECACC) are an IL-2 producing T lymphocyte cell line, commonly used to study 
T cell signaling. Established from the peripheral blood of a 14 year old boy with T cell leukemia, 
Jurkat cells are also useful for studying acute T cell leukemia. Jurkat cells are also useful for 
analysis of T cell signaling, including p38 MAPK, JNK signaling, and NF-kB signaling. 
EoL-1 cells (ECACC), a recently established human eosinophilic leukemia cell line, have 
cytological features of myeloblasts under normal culture conditions, and differentiate not only 
phenotypically but also functionally into eosinophils by a number of stimuli. EoL-1 cells are 
particularly useful for analyzing leukemic cell differentiation and the properties of malignant 
eosinophils. EoL-1 cells are also a useful in vitro model for studying human eosinophil functions 
and their regulation.  
Jurkat E6.1, K-562 and EoL-1 were maintained as a stationary suspension culture in RPMI-1640 
with 10% fetal bovine serum  (FBS) and  a mixture of antibiotics and antimycotics. 
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TF-1 cell line was a kind gift by professor Giorgio Gallinella (Department of Pharmacy and 
Biotechnology, University of Bologna, S. Orsola-Malpighi Hospital). The TF-1 cell line was 
established in October 1987 from a heparinized bone marrow aspiration sample from a 35 year old 
Japanese male with severe pancytopenia. The cells are completely dependent on interleukin 3 (IL-3) 
granulocyte-macrophage colony-stimulating factor (GM-CSF) for long term growth. The 
morphological and cytochemical features, and the constitutive expression of globin genes, indicate 
the commitment of the cells to the erythroid lineage. Hemin and delta-aminolevulinic acid induce 
hemoglobin synthesis, and TPA induces dramatic differentiation of the TF-1 cells into macrophage-
like cells. The TF-1 cell line is unique because of its responsiveness to multiple cytokines. The base 
medium for this cell line is RPMI-1640 (Lonza), with the following components: 2 ng/ml 
recombinant human  IL-3, fetal bovine serum to a final concentration of 10% (FBS) and a mixture 
of penycillin/streptomycin 1%. 
RPMI 8866 cell line has a lymphoblastoid morphology; they were a kind gift from professor 
Santoni Angela (Laboratory of Molecular Immunology and Immunopathology, Department of 
Molecular Medicine, “Sapienza”  University  of  Rome). This cell line has been established from the 
peripheral blood of a 51-year-old American woman with chronic myelogenous leukaemia in May 
1966. The B lymphoid cell line expresses a relatively high amount of calcitonin receptors, 
membrane bound Ig and soluble IgE-binding factor (Fc epsilon RII/CD23). Culture medium is 
RPMI 1640 (Lonza) with 10% Fetal Bovine Serum (FBS),enriched with Hepes 5 mM and sodium 
pyruvate 0,5 mM. Cells are usually kept in 50 mL of culture medium and they form large clumps. 
HMC 1.1 cells were kindly provided by professor Butterfield Joseph. H. (Mayo Clinic, Division of 
Allergic Diseases, Rochester, Minnesota, USA). The growth factor-independent human mast cell 
line, HMC-1.1  was  grown  in  IMDM  medium  (Iscove’s  medium  with  25  mM  Hepes)  supplemented 
with sodium carbonate (3,02 g/L), l-glutamine (2 mM), 1,2 mM alphathioglycerol (Sigma), FBS 
(10%), penicillin (100 units/ml), and streptomycin (100 µg/ml). HMC-1.1 is a factor-independent, 
immature mast cell line derived from the peripheral blood of a patient suffering from mast cell 
leukemia. In fact, two subclones, HMC-1.1 and HMC-1.2, have been characterized. HMC-1.1 has a 
KIT V560G mutation, whereas HMC-1.2 has two KIT mutations (V560G and D816V). 
Adherent cells were detached with trypsin or with a cell scraper and viability was determined using 
trypan blue staining. Cells were kept at a temperature of 37 °C, a minimum relative humidity of 
95% and an atmosphere of 5 % CO2 in air. For all experiments, cells were used between passage 3 
and 15. 
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5.1.3 Cell adhesion assays  
Cell adhesion assays were performed with all cell lines previously described. Briefly, 96-well plates 
were coated at 4°C overnight with different concentrations of ligands: 
 
 FN     VCAM-1  ICAM-1 
Jurkat E6.1     10µg/mL    2 µg/mL  2 µg/mL 
Eol-1    25µg/mL    5 µg/mL                / 
HMC 1.1                /    2 µg/mL                / 
TF-1    10µg/mL    1 µg/mL               / 
RPMI 8866    10µg/mL    2 µg/mL               / 
K562   10µg/mL                  /    / 
SK-MEL-24   10µg/mL                  /   / 
D283   10µg/mL                  /  / 
 
The   employ   of   different   ligand   agonist   concentrations   was   justified   by   different   levels   of   α4E1 
integrin expression on cell surfaces. Cell adhesion assays with Jurkat E6.1, Eol-1, HMC1.1, TF-1 
and RPMI8866 were done as  described below. Non-specific hydrophobic binding sites were 
blocked by incubation with a BSA 1%/HBSS (w/v) solution for 30 minutes at 37°C. The day of the 
assay, the cells were counted and stained with 12.5 PM CMFDA (30 minutes at 37°C). After three 
rinses with BSA/HBSS to wash away the excess dye, different aliquots of cells were divided among 
a number of tubes corresponding to the number of treatments. For inhibition experiments, cells were 
mixed with the drug and pre-incubated at 37°C for 30 minutes to reach equilibrium before being 
plated. After 30 minutes incubation at 37°C in the coated wells, the non-specifically bound cells 
were washed away with BSA/HBSS solution. Adherent cells were lysed by the addition of 0.5% 
Triton X-100 in PBS (30 minutes at 4°C).  Released CMFDA was quantified by fluorescence 
imaging at Ex485 nm/Em535 nm (Wallac ARVO 1420 multilabel counter) and adherent cells was 
counted by interpolation on a standard curve. The number of adherent cells was calculated by 
comparison with a standard curve prepared in the same plate using known concentrations of labeled 
cells.  
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K562, SK-MEL-24 and D283 cell adhesion assays were carried out in a slight different way. Cells 
were counted with a hemocytometer and pre-incubated with various concentrations of each 
compound for 30 minutes at room temperature to reach a ligand–receptor equilibrium. At the end of 
the incubation time, the cells were plated (50000 cells per well) and incubated at room temperature 
for 1 hour. All the wells were then washed with PBS to remove non adherent   cells,   and   50   μL  
hexosaminidase [4-nitrophenyl-N-acetyl-β-d-glucosaminide dissolved at a concentration of 7.5 mM 
in 0.09 M citrate buffer (pH 5) and mixed with an equal volume of 0.5% Triton X-100 in H2O] was 
added.   This   product   is   a   chromogenic   substrate   for   β-N-acetylglucosaminidase, whereby it is 
transformed into 4-nitrophenol; absorbance was measured at 405 nm. The reaction was blocked by 
the  addition  of  100  μL  of  a  stopping  solution  [50  mM  glycine  and  5  mM EDTA (pH 10.4)], and the 
plates were read in a Victor2 Multilabel Counter (PerkinElmer, Waltham, MA, USA).  
The efficacy of putative antagonists (at least eight different concentrations were used) was 
determined by the reduction in adherent cells compared to the untreated control. Each experiment 
was conducted in quadruplicate and the data are presented as the mean ± S.E.M. of at least three 
independent assays. Data analysis and IC50 values were calculated using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA, USA). 
 
5.1.4 Scintillation proximity assay (SPA) 
The radioligand binds to the α4E1 integrin and the close proximity of the isotope to the scintillant 
incorporated in the beads allows the radiation energy to transfer to the scintillant where it can be 
detected as counts per min (cpm). FN was labeled with Na[125I] using the IodogenKit, as specified 
by the manufacturer (Pierce). 125I-FN was purified from unincorporated iodine by gel filtration 
chromatography on PD-10 columns; trichloroacetic acid-precipitable radioactivity was 6.30 x 1010 
PCi/mol. The experiments were carried out in scintillation vials; in each vial 1 mg/50 Pl anti-rabbit-
coated beads, 400 ng of rabbit anti-α4 integrin antibody and a portion of cell eluate (containing 
approximately 100 Pg of α4E1 integrin) were added. The α4E1 integrin was extracted from Jurkat 
cells (cultured in RPMI 1640 medium containing L-glutamine, 10% FBS, antibiotic-antimicotycotic 
solution and kept in a humidified incubator at 37°C in a 5% CO2 atmosphere). The cells were 
collected and then cytoplasmic proteins were extracted with the T-PER extraction buffer and α4E1 
integrin was purified by affinity chromatography. For Western blot experiments on extracts we used 
antibodies against α4 and E1 integrin subunits to confirm that both integrins partitioned to the cell 
lysate collected from the affinity column. The binding buffer contained Tris-HCl 25 mM pH 7,5; 
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CaCl2 1 mM; MgCl2 1 mM; MnCl2 1mM; BSA 2% (w/v); phenylmethanesulfonyl fluoride (PMSF) 
1 mM; aprotinin 1 mg/ml; leupeptin 50 mM. 
First, we allowed for the slow interaction between the α4 integrin protein and the compound under 
examination by incubating together for 1,5 hours at room temperature. Then we added the rabbit 
anti-human α4 integrin antibody, followed by an incubation time of 2 hours at 4°C. From this point 
on, all incubations were conducted at room temperature.  
Then the anti-rabbit antibody binding beads were added, and the solution containing the four 
components was incubated for 2 hours  at room in the dark. 125I-FN was added to the vials, which 
were then incubated overnight on a shaker in the dark. The samples were read using a LS 6500 
multipurpose scintillation counter (Beckham Coulter, Fullerton, CA, USA). The SPA procedure 
was optimized in preliminary experiments. 
  
5.1.5 Western Blotting 
Total protein fractions were obtained using the commercial T-PER Tissue Protein Extraction 
Reagent (Pierce): lysis and resuspension buffer contained a mixture of protease inhibitors composed 
of 0,5 mg/mL Benzamidine, 2 µg/mL Aprotinin, 2 µg/mL Leupeptin, 2 mM phenylmethlysulfonyl 
fluoride, and a cocktail of phosphatase inhibitors 100x (Sigma).  
The first step is the addition of appropriate amount of T-PER Reagent to each sample; cells are 
strikingly resuspended to permit lysis. After 10 minutes of gently agitation at 4 °C, samples were 
centrifuged at 10,000 g for 10 minutes to collect supernatants. Protein samples were then kept at – 
80°C, and protein concentration was determined using the Lowry method [Lowry et al., 1951]. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting 
were performed according to standard procedures: proteins from the total extract (100 µg) were 
separated by SDS-PAGE at different polyacrylamide concentration: 12% for detection of 
phosphoERK 1/2 and 7,5% for detection of phosphoFAK  and  integrin  subunit  α4. 
Briefly, all gels were transferred onto a Hybond-ECL nitrocellulose membrane (GE Healthcare) 
after three hours of run at constant mA. As a molecular weight standard, it was used the Magic 
Marker XP (Invitrogen). 
All blots were blocked with 5% non-fat milk in TBS 1X (10mM Tris-HCl, pH8, containing 150mM 
NaCl) plus 0,1% Tween-20 for 1 hour at room temperature, except for total ERK (as loading 
control) that required a 1 hour incubation with TBS 1X plus 1% BSA at 37 °C in gentle agitation. 
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To detect phosphoERK 1/2, phosphoFAK and total FAK membranes were incubated overnight at 
4°C with specific rabbit polyclonal IgGs (Cell Signaling), used at a dilution of 1:1000 in TBS 1X, 
0,1% Tween-20 and BSA 5%.   
For detection of total ERK (as loading control), primary antibody (Promega) was used at a 
recommended diluition of 1:5000 in TBS 1X, 0,1% Tween-20 and BSA 0,1%, for two hours at 
room temperature.   
For detection of integrin subunit   α4 and β1, it was used, respectively, a 1:200 and 1:500 primary 
antibody dilution in blocking buffer for 1,5 hours at room temperature.     
All the membranes were incubated with peroxidase-conjugated secondary antibodies at a dilution of 
1:8000 (goat anti-Rabbit HRP conjugated IgG; Santa Cruz), for 1,5 hours at room temperature, 
except for integrin subunit  α4  and phosphoFAK that required the same antibody, with a diluition of 
1:4000. For  integrin  subunit  β1, instead, a goat anti-mouse HRP conjugated IgG (Santa Cruz) was 
used at 1:4000 diluition for 1,5 hours at room temperature. 
Detection of immunoreactive bands was done by the enhanced chemiluminescent method 
(Immobilon Western Chemiluminescent HRP Substrate – Millipore) and a FUJILAS3000 
acquisition camera. 
 
 
5.1.6 β-hexosaminidase release assays 
Degranulation from HMC 1.1 cells was monitored by measuring the activity of  a granule enzyme 
β-hexosaminidase released in the cell supernatants after appropriate treatments.  
In the first set of experiments, Jurkat T cells (1x105 cells for each well) were pre-incubated for 30 
minutes in the presence of phorbol myristate acetate (PMA; 50 ng/mL) at 37 °C in normal culture 
medium, washed three times with RPMI 1640, and co-coltured with an equal number of mast cell 
previously treated with different concentration of DS70 at 37 °C for 60 minutes in a volume of 100 
µL. Medium used for co-colture is composed by IMDM  (Iscove’s  Modified  Dulbecco’s  Medium), 
L-glut (2mM) and BSA 0,1%. After 22 hours, 96-well plate is centrifuged for 2 minutes at 3000 
rpm; then, aliquots of 50 µL of the supernatants of each well were transferred to a separate 96-well 
plates. Fifty microliters of substrate solution ([4-nitrophenyl-N-acetyl-β-d-glucosaminide dissolved 
at a concentration of 7.5 mM in 0.09 M citrate buffer (pH 5) and mixed with an equal volume of 
0.5% Triton X-100 in H2O]) were added to each sample and the plates were incubated for 90 
minutes at 37 °C. The reaction was stopped by addition of 100 µL of stopping solution [50 mM 
glycine and 5 mM EDTA (pH 10.4)], following by reading the absorbance at 405 nm. Each sample 
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was evaluated in triplicate. Degranulation is expressed as percentage   of   the   cells’   total  mediator  
content obtained by lysis of cells with Triton X-100 0,2%.  
In another set of experiments, 1x105 HMC 1.1 cells per each well were pretreated at 37 °C for 60 
minutes with different concentrations of compound DS70 in a final volume of 100 μl . All the assay 
was   performed   in   sterile   Tyrode’s   buffer   (NaCl 137 mM; KCl 2,7 mM; CaCl2 1,8 mM; MgCl2 
1mM; glucosio 5,6 mM; Hepes 20 mM; BSA 0.1%, Ph 7.4).  
Positive controls include treatments with PMA 100 nM e calcimycin 1 µM at 37 °C for 30 minutes. 
Calcimycin, also known as ionophore A23187, is a polyether antibiotic from Streptomyces 
chartreusensis. It binds and transports calcium and other divalent cations across membranes. The 
substance is used mostly as a biochemical tool to study the role of divalent cations in various 
biological systems. 
Controls included cells mixed with 0.2% Triton X-100 to measure  total  β-hexosaminidase release, 
and   samples   mixed   with   Tyrode’s   buffer   (vehicle control) as a measure of background   β-
hexosaminidase release. Each sample was run in triplicate. After incubation with controls or test 
samples, each well is assayed for the  presence  of  β-hexosaminidase as previously described.  
Percent (%) degranulation was calculated using the following equation: (experimental  β-hex release 
– vehicle control  β-hex release) / (Triton X-100  β-hex release–vehicle  control  β-hex release) x 100. 
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5.2 IN VIVO EXPERIMENTS 
 
5.2.1 Animals 
Male Dunkin-Hartley guinea pigs (250-300 g) were purchased from Charles-River (Calco, Italy). 
Animals were handled in accordance with the Guiding Principles in the Care and Use of Animals of 
the University of Bologna. Furthermore, all experiments conformed to the ARVO (Association for 
Research in Vision and Ophthalmology) resolution on the Use of Animals in Research. 
 
5.2.2 Animal experiments 
The method used has been described by Khosravi and colleagues in 1995 and by Ebihara and 
colleagues in 1999.  
40 male Dunkin-Hartley guinea pigs were divided into 4 groups of 6 animals each. At day zero, 2 
ml of a saline solution containing 100 Pg/mL ovalbumin (OVA) and 20 mg/mL Al(OH)3 as 
adjuvant, were injected intraperitoneally (i.p.) to each of the animals, except for the negative 
control. Treatment was repeated two weeks  and three weeks later.  
Four weeks after the first OVA immunization, all animals were challenged with 30 PL per eye of 
saline solution, containing 100 mg/mL ovalbumin. DS70 powder was dissolved, at the moment, in a 
vehicle containing 10% PEG 3350/1%PS80, Phosphate Buffer pH 7.0.  
One month after the first immunization, compound DS70 (0.1% weight/volume) eye drops were 
instilled  into  the  conjunctival  sac  (30  μl/eye)  of  the  treated  guinea pigs: 30 and 10 minutes before 
the animals were challenged with 30 ml/eye of saline solution, containing 100 mg/ml OVA, 
instilled into the conjunctival sac. Negative controls received saline alone.  
 
Conjunctival clinical symptoms were rated blind on both eyes using the following scale: 0, no 
symptoms; 1, slight conjunctival redness with or without tears; 2, mild conjunctival redness with 
tears and mild chemosis; 3, mild conjunctival redness with tears and moderate chemosis; 4, severe 
conjunctival redness with tears and partial lid eversion; 5, severe conjunctival redness with tears 
and lids more than half closed. Pictures of both eyes were taken to evaluate the clinical score 1, 2, 4, 
6 and 24 hours after topical ovalbumin administration. The animals were euthanized 24 hours after 
OVA challenge by i.p. injection of Tanax® (3 ml/kg; Hoechst AG, Frankfurt-am-Main, Germany). 
Tarsal conjunctiva of both eyes, was collected to carry out the experiments thereafter described. 
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5.2.3 Collection of ophthalmic lavage fluid (OLF) 
The collection of OLF was carried out as follows: a 30-μl  aliquot  of  assay  buffer  consisting  of  0.3  
M sucrose in 50 mM sodium acetate buffer pH 5.4 with 10 units/ml heparin was applied to the eye 
using a micropipette, without touching the eye. After two or three  forced  blinks,  the  30  μl  of  lavage  
fluid   was   collected.   The   lavage   was   repeated   3   times   in   each   eye   (90   μl   /animal),   and was 
conducted at 1, 2, 4, 6 and 24 hours after topical ovalbumin administration. 
 
5.2.4 Measurement of eosinophil peroxidase (EPO) activity in tears 
EPO activity in the OLF was measured according to the method of  Tagari and colleagues. Briefly, 
following the centrifugation (4°C, 300 g, 15 minutes)  of  the  fluid,  thirteen  μl of sample was added 
to 80-μl  aliquots  of  sucrose  assay  buffer  (see  collection  of  OLF)  with  or  without  3  mM  (final)  KBr,  
in a 96 well plate. 3,3',5,5'- Tetramethylbenzidine (TMB) liquid substrate system liquid (Sigma) 
was  added  in  a  volume  of  40  μl  and  mixed. All solutions were previously warmed to 21°C. 
After 10 minutes of  incubation,  the  peroxidase  reaction  was  stopped  by  the  addition  of  60  μl  of  2  N  
H2SO4. Absorbance at 450 nm was measured. 
 
5.2.5 Eosinophil peroxidase assay 
Eosinophil peroxidase assay was performed as previously described by Izushi and colleagues in 
2002: 24 hours after conjunctivitis induction, by application of the antigen, the guinea pigs were 
sacrificed and the upper and lower parts of the tarsal conjunctiva were excised, cleaned, weighed 
and washed twice with ice-cold PBS. The tissues were homogenized with 50 mM Tris-HCl buffer 
(pH 8.0) using a Potter-Elvehjem glass/Teflon homogenizer (Wheaton, Millville, NJ, USA) on ice. 
The homogenates were placed in ice bath for 1 hour, after addition of 350 PL of 50 mM Tris-HCl 
buffer and 150 PL of 0.1 % Triton X-100. Then, the substrate solution (400 PL of 50 mM Tris-HCl 
buffer containing 0.1 % Triton X-100, 1 mM o-phenylenediamine, and 0.5 mM hydrogen peroxide) 
was added to 200 PL of the sample and incubated at 37 qC for 10 minutes. The reaction was 
stopped with 200 PL of 4 M H2SO4. Absorbance was measured, using a spectrophotometer (JASCO 
V-530, Jasco, UK), at 490 nm. 
 
 
Chapter 5 – Materials and Methods 
48 
 
5.2.6 Quantitative PCR analysis of cytokines and chemokines in tarsal 
conjunctiva 
Tarsal Conjunctiva specimens were stored in RNAlater at -20°C. Total RNA was extracted from 
homogenized conjunctivae with TRI Reagent and measured using a spectrophotometer. For each 
conjunctival sample, 1 μg of total RNA was treated with RNase-free DNase for 15 minutes at 25°C, 
followed by incubation at 65°C for 10 minutes to inactivate DNase. The RNA samples were then 
converted into cDNA using oligo(dT), random primers, and the High-Capacity cDNA Reverse 
Transcription   Kits   according   to   the   manufacturer’s   instructions.   Real   time   PCR   was   performed  
using GoTaq® qPCR Master Mix. The protocol consisted of denaturation at 95°C for 10 minutes, 
followed by 40 cycles of 95°C denaturation (20 s) and 58°C annealing (1 min). No-template 
controls and DNA melting curve analysis were used as controls to ensure the lack of contaminating 
DNA in the RNA preparations and to rule out primer-dimer formation, respectively. Induction of 
mRNA was determined from the threshold cycle (Ct) values normalized for GAPDH expression and 
then normalized to the value derived from conjunctivae of not immunized guinea pigs. Real time 
PCR primers for guinea pig genes evaluated in this project are listed in Table 1. Primer sequences 
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), interleukin-1β   and   eotaxin   (CCL11)  
were published by Kubo and colleagues in 2005; primer sequences for RANTES (CCL5) were 
published by Lacy and colleagues in 2011. All primers were synthesized by Sigma-Aldrich. 
 
Table 1. Primers for real-time PCR 
mRNA targets Sense primer Antisense primer 
GAPDH CCGGCCAAATACGATGACAT TGTAGCCCAAGATGCCTTTGAG 
IL-1β CATGAGCTTCGTACAAGGAGAAAG CAGGTACAGATTCTTCCCCTTGA 
Eotaxin 
(CCL11) 
TCTGCACACTGCACCATGAA AAGCAGAGACTGTGAGCAGCA 
RANTES 
(CCL5) 
CTGGCCCACTGCTTAGCAAT CCTTGCTTCTTTGCCTTGAAA 
IL-8 CCTTGGATTCCCCTTTATTCCT CGTATGTCCCCATGACATTGTG 
 
 
5.2.7 Immunostaining for α4 subunit 
Tissues were fixed in formaldehyde and embedded in paraffin before cutting, and staining was 
performed by using a peroxidase-based   method.   Briefly,   sections   of   6   μm   in   thickness   were  
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deparaffinated in xylene, dehydrated in ethanol, and washed in water. Heat mediated antigen 
retrieval was performed with citrate buffer (pH 6.0) for 20 minutes and the sections were washed 3 
times in TBS-T (TBS + 0.025% Tween-20). Immunohistochemical staining was made using Rabbit 
specific HRP/DAB detection kit (Abcam) following  manufacturer’s  instructions.  Briefly,  specimens  
were incubated with Protein Block solution for 5 minutes at room temperature to block nonspecific 
background staining. After washing once in TBS-T, tissue sections were incubated with antibodies 
that recognized human integrin α4 (diluted 1:500) overnight at 4°C. The specimens were washed 4 
times in TBS-T and incubated with Biotinylated goat anti-mouse IgG for 30 minutes at room 
temperature. 
Slides were then developed with streptavidin-biotin complex/horseradish peroxidise (HRP) and 
diaminobenzidine substrate (DAB), according to the manufacturer's instructions. Haematoxylin was 
used as background staining. Sections were examined with standard light microscope (Nikon 
Eclipse E800) in a blinded manner and photomicrographs were taken with a 20x objective. 
 
5.2.8 Giemsa staining for mast cells degranulation 
Gustav Giemsa was born in Germany in 1867, worked mainly as a chemist, and died in 1948. The 
staining method, which carries his name, was designed primarily for the demonstration of parasites 
in malaria, but it was also employed in histology because of the high-quality staining of the 
chromatin and the nuclear membrane, the metachromasia of some cellular components, and the 
different qualities of cytoplasmic staining depending on the cell type. The use of methylene azure 
and its mixture with methylene blue to form an eosinate made stable the stain and its results.  
Giemsa Stain is a buffered thiazine-eosinate solution designed to provide coloration of blood cells 
similar to the original product described by Giemsa. Nuclei will be varying shades of purple. 
Cytoplasmatic staining will be varying shades of blue to light pink. Fine reddish to lilac granules 
may be present in cytoplasm of some cell types. Basophils will demonstrate dark blue black 
granules in the cytoplasm. Eosinophils will demonstrate bright orange granules in the cytoplasm. 
Red blood cells should be pink to orange. 
Sections are dewaxed, rinsed in alcohol and then in water. Staining with Giemsa (diluited 1:10 in 
bidistilled water) last two hours at room temperature. After one wash in water, blots were dried out, 
rinsed briefly in alcohol, and mounted to be examined with standard light microscope.  
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6.1 IN VITRO RESULTS 
 
6.1.1 Binding affinity of library compounds to human α4β1 integrin by SPA 
and α4β1/VCAM-1-mediated cell adhesion in vitro 
Jurkat cells, expressing  human  α4β1 integrin, were used to measure peptidomimetic binding to α4β1 
integrin by SPA. To purify receptor proteins, an affinity chromatography column was used. The 
presence of glycosidic groups in  subunit  α4 allows a specific interaction with  WGA (wheat-germ 
agglutinin) columns. Once the interaction is established, proteins are eluted with a concentrated 
solution of N-acetylglucosamine (200 mM), which allows the removal of proteins specifically 
bound to the resin. Western blot analysis, performed with specific antibodies for α4 and β1 integrin 
subunits confirmed that both subunits are present in all fractions of eluate employed for the SPA 
(Figure 7.1, panel A). Specific binding of 125I-FN to an antibody-captured  α4β1 integrin was time-
dependent; the signal increased during the first 10 hours, then reached a plateau and remained 
constant for the remainder of the 24 hours incubation (data not shown). The relatively slow kinetics 
of the SPA may require the establishment of an equilibrium between the different components. 125I-
FN specific binding, measured after overnight incubation, was concentration-dependent (Figure 7.1, 
panel  B)  and  was  blocked   in   the  presence  of  100  μM  BIO-1211 (a potent α4β1 and αLβ2 integrin 
antagonist) to capture the integrin complex (data not shown).  The straight sequence MPUMP-β2-
Pro-Asp-OBn BL31 was not able to inhibit 125I-FN binding. On the contrary, the retro compounds 
BL16–DS45 caused a concentration-dependent inhibition of 125I-FN binding (Table 1). The 
sequence BnCO-Asp-β2-Pro-AMPUMP BL16 showed IC50 and Ki values (M) of 1.0 × 10−7 and 
6.0 × 10−8, respectively. The analog of BL16, named DS64, containing isoAsp, has an IC50 of 
2.9 × 10−7 M and Ki of 1.8 × 10−7 M. DS45 equipped with the 2,6-dicholorobenzoyl group revealed 
a modest affinity, in the micromolar range, while BL25, analog of DS64 with the 2,6-
dicholorobenzoyl instead of the phenylacetyl (BnCO) group, did not displace 125I-FN significantly.  
The same behaviour is observed comparing RDM355 and its analog RDM416: the first shows an 
interesting value of IC50 equal to 34× 10−9 M, instead RDM416 looses its activity. DS23 share some 
characteristic structures with DS70, as the introduction of beta proline to confer rigidity to 
molecule, but the fundamental carbossilic moiety is beared by a malonate group. However, it shows 
a noticeable IC50, equal to 48 × 10−9  M. 
DS70 results the most potent one: it caused concentration-dependent inhibition of 125I-FN binding 
to the SPA bead-associated α4β1 integrin (Figure 6.1, panel C) with an IC50 of  22 × 10−9  M. 
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Figure 6.1 A, Representative autoradiogram of a Western blot experiment, evaluating the  α4 and  β1 integrin 
subunits in cell lysates fractions (E1, E2, E3) of Jurkat cells, expressing α4β1 integrin. The lysates were 
purified by affinity chromatography and three fractions of approximately  150  μl  were  collected;;  the  presence  
of  α4 integrin was confirmed in all the fractions. These fractions were then assayed to confirm the presence 
of the β1 integrin  subunit.  Approximate  molecular  masses  of  the  α4 and  β1 integrin subunits were determined 
by comparison with molecular mass standards. B, Saturation SPA binding of [125I]-FN to the purified α4β1 
integrin extracted from Jurkat cells and incubated with increasing concentrations of the radioligand (cpm). 
Non specific binding was determined in the presence of unlabeled fibronectin. Specific binding obtained by 
subtraction of the non-specific binding from total binding counts. C,  Inhibition of [125I]-FN binding by DS70 
in the SPA. Binding to Jurkat E6.1 cell lysates was measured in the presence of increasing concentrations of 
compound and of a fixed amount of [125I]-FN (100.000 cpm) as described under materials and methods. 
Mean ± S.E.M. of three experiments done in triplicate.  
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We assayed the ability of a small library of compounds capable to inhibit cellular adhesion of α4β1 
integrin-expressing Jurkat cells to VCAM-1. In a first set of experiments, we ascertained that 
adhesion of these cells to 96-well plates coated with human recombinant VCAM-1 was 
concentration-dependent and was not observed in BSA-coated wells. 
 As shown in Table 1, peptidomimetics BL31, BL25 and DS45 did not affect cell adhesion to any 
significant extent. Interestingly, the retro compounds BnCO-Asp-β2-Pro-AMPUMP BL16 and 
BnCO-isoAsp-β2-Pro-AMPUMP DS64 inhibit cell adhesion with an IC50 of 0,16 and 0,20 × 10−6  
M, respectively. On the contrary, DS45 fails to behave as antagonist, despite the micromolar 
affinity revealed by the SPA (Table 1). DS70 also in this case shows the most potent  IC50, equal to 
2 x 10-9 M (Figure 6.2). 
Finally, neither compounds (up to 2 mM) influences cell viability, evaluated by Trypan blue 
exclusion (data not shown). 
 
 
 
 
 
 
 
 
Figure 6.2  Concentration–response curve showing the effects of  DS70 on Jurkat E6.1 cell adhesion VCAM-
1 mediated.  Results are expressed as the number of cells attached ± S.E.M from quadruplicate wells and 
repeated at least three times. 
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Table 1 SPA binding  to bead-associated α4β1 integrin and IC50 inhibition values of Jurkat E6.1 cell 
adhesion VCAM-1 mediated of peptidomimetic library compounds. Mean ± S.E.M. of at least five 
experiments done in triplicate. 
 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Structure SPA
IC50 (µM)
SPA
Ki (µM)
Adhesion assay -
α4β1 integrin-mediated
adhesion on VCAM-1 - IC50
(µM)
RDM355 0,034 ± 0,005 0,021 ± 0,004 0,011 ± 0,004 
RDM416 n.a. n.a. 1,5 ± 0,7
DS70 0,022 ± 0,003 0,014 ± 0,002 0,0020 ± 0,0005
DS23 0,048 ± 0,004 0,030 ± 0,003 0,040 ± 0,007
BL16 0,18 ± 0,06 0,11 ± 0,03 0,16 ± 0,01
DS64 0,63 ± 0,02 0,38 ± 0,04 0,20 ± 0,05
DS45 4,30 ± 0,48 2,72 ± 0,24 n.a.
BL25 n.a. n.a. n.a.
BL31 n.a. n.a. n.a.
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6.1.2   DS70   inhibits   α4β1 integrin-mediated cell adhesion in different cell 
lines 
To determine efficacy and potency of DS70, we have developed cell adhesion assays using different 
cell lines and different ligands. 
Once confirmed blockade of Jurkat cells adhesion to VCAM-1, we proceeded to analyze its 
selectivity  within  the  family  α4: we tested compound DS70 in a cell line expressing integrin  α4β7, 
RPMI8866 (Figure 6.4). Inhibition curve shows that this compound maintains a good capacity of 
inhibition of cellular adhesion to fibronectin (10  μg/ml). The IC50 value is equal to 340 × 10−9  M: it 
is lower than observed towards the  integrin  α4β1.  
Adhesion assays carried out on cell line Jurkat E6.1 using the ligand agonist ICAM-1 confirmed 
that inhibition of cell adhesion determined from DS70 is mediated by α4β1 or  α4β7 integrin, not by 
αLβ2 integrin, both expressed on these cells. 
DS70 was found to inhibit the cellular adhesion in all cell lines expressing α4β1 integrin: in HMC 
1.1 cell line IC50 value is equal to 218 × 10-9 M; in Eol-1 cell line, values are equal to 26 × 10-9 M, 
and 36 × 10-9 M for FN-mediated cell adhesion; in TF-1 cell line, IC50 values are equal to 72 × 10-9 
M for VCAM-1 mediated cell adhesion, and 218 × 10-9 M for FN- mediated one. 
We can, therefore, conclude that DS70  behaves  as  a  α4β1 or  α4β7 dual antagonist. To investigate any 
selectivity of molecule, adhesion assays on other cell lines expressing the major subtypes of 
integrins were carried out. 
As regards to integrin α9β1, DS70 acts as a partial agonist of the cellular adhesion, with a value of 
EC50 equal to 3.8 × 10-9 M. Towards integrin  αvβ3 and  α5β1, on the other hand, this compound fails 
to show any activity (Figure 6.4). 
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Figure 6.3 Schematic representation of characteristic sigmoidal curves of cell adhesion inhibition in all cell 
lines  expressing  α4β1 integrin induced by different agonists: panel A, Jurkat E6.1 cell line, panel B, HMC 
1.1; panel C, Eol-1 cell line; panel D, TF-1 cell line. Mean ± S.E.M. of three experiments done in triplicate. 
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K562 cell line (chronic myelogenous leukemia)                         RPMI 8866 (lymphoblastoid leukemia) 
 
 
 
                                                          
       
 
 
                                                SK-MEL-24 cell line (human melanoma) 
 
 
 
 
                                                         D283 cell line (medulloblastoma)   
 
 
 
 
 
Figure 6.4 Analysis of cellular adhesion mediated by fibronectin in the presence of increasing 
concentrations of DS70 compound carried out in three different cell lines: panel A, K562 cells, which 
express   integrin   α5β1;panel B, RPMI8866, which express integrin   α4β7; panel C, SK-MEL-24 cells, that 
express   integrin  αvβ3; panel D, cells D283, expressing integrin α9β1. Mean ± S.E.M. of three experiments 
done in triplicate. 
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6.1.3 Effect of DS70 on fibronectin and VCAM-1-induced ERK 1/2 and 
FAK phosphorylation in different cell lines 
 
Integrins activate intracellular signaling pathways through the recruitment of Src-family kinases 
(SFKs). Most integrins recruit focal adhesion kinase (FAK) through their β subunits. FAK functions 
as a phosphorylation-regulated scaffold to recruit Src to focal adhesions. FAK also activates 
extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) by recruiting 
the RAP1 guanine nucleotide-exchange factor (GEF). RAP1 then activates ERK/MAPK through B-
Raf. Alternatively, FAK can activate ERK/MAPK by recruiting the growth-factor-receptor-bound-2 
(GRB2) and son-of-sevenless (SOS) complex. We chose to evalutate DS70 ability to modulate 
integrin signaling,  performing  Western  blot  analysis  in  several  cell  lines  expressing  α4β1 integrin. 
All cell lines, 24 hours before treatment, were cultured in medium containing 1% fetal bovine 
serum (FBS), in order to reduce any interference of serum components.  
The first step was a pretreatment of 30 minutes (Jurkat cells) or 60 minutes (all others cell lines) at 
37 °C with DS70 at a different concentrations; subsequently, soluble VCAM-1 (2 µg/ml for Jurkat 
cells), FN at concentration of 25 µg/ml for Eol-1 cell line and 1 µg/ml for TF-1 cell line were 
added.   
To assess the expression of  phosphorylated FAK in the Jurkat cell line, we used a sensitive 
antibody to detect the phosphorylation of tyrosine 197, showing a band with apparent molecular 
weight of approximately 125 kDa. As can be seen in figure 6.5, VCAM-1 is able to significantly 
increase the levels of phosphorylation of FAK, confirming activation of integrin α4β1 intracellular 
signaling. Preincubation of cells with DS70 10-6 M significantly reduces FAK phosphorylation. 
Similar effects were observed as regards to levels of phosphorylation in Jurkat cells: VCAM-1 was 
able to stimulate phosphorylation of ERK1/2, while DS70 is capable of reversing this positive 
effect. 
Interestingly, I observed an unusual behavior of DS70: at lower concentrations it significantly 
reduces phosphorylation levels of ERK1/2, wherease it was less effective at higher concentrations. 
This phenomenon deviates from normal trend of a classical drug, which may be represented by a 
sigmoid dose-dependent. In this case, the maximum magnitude of cellular response was observed 
with pre-incubation with DS70 at 10-7 M. A possible explanation of this phenomenon occurs in the 
observation that higher concentrations may cause a loss of efficacy due to the tight interaction of 
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DS70 with the integrin. So, DS70 seems to possess a different behaviour in this cell line: I suggest a 
bell-shape trend.  
Treatments of Eol-1 cell line was performed as previously described: I investigated a wide range of 
DS70 concentrations. Fibronectin was chosen as ligand agonist because of its efficacy to activate 
integrin mediated signaling. In figure 6.6 is reported ERK 1/2 phosphorylation levels induced by 
fibronectin, and the efficacy of DS70 to act as an antagonist. 10-6 M resulted the most efficacious 
concentration, reconfirming a peculiar characteristics of DS70 already highlighted in Jurkat E6.1 
cell line. 
In TF-1 cell line, according to preliminary studies, I used a lower concentration of the agonist 
ligand fibronectin (1 µg/ml) as  this cell line exhibits an higher adhesive ability. Consequent to this 
are reduction of agonist concentrations used in this study, and viceversa increase of peptidomimetic 
concentrations analyzed. In these experimental conditions, DS70 blocked fibronectin mediated cell 
adhesion at 10-7 M (Figure 6.8). 
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Figure 6.5 DS70 antagonizes VCAM-1 induced phosphorylation of FAK. Phosphorylation levels of FAK 
protein in Jurkat cells E6.1 exposed to VCAM-1 2 µg/ml for 120 minutes in the presence or absence of the 
compound DS70 at a concentration of 10-6 M are shown. Panel A, autoradiogram of a representative 
experiment. Panel B, quantification of the optical density of the individual bands. # # # p<0.001 vs CTRL; 
*** p<0.001 vs VCAM-1 120' (Newman-Keuls test after ANOVA) [Mean ± S.E.M.; n=6]. 
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Figure 6.6  Expression of phosphorylation levels of ERK 1/2 proteins in Jurkat cells E6.1 exposed to VCAM-
1 2 µg/ml for 30 minutes in presence of compound DS70 at a concentration of 10-6, 10-7 and 10-8 M. Panel A, 
autoradiogram of a representative experiment. Panel B, quantification of the optical density of the individual 
bands. No significance was observed with Newman-Keuls test after ANOVA. Mean ± S.E.M.; n=6. 
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Figure 6.7 Expression of phosphorylation levels of ERK 1/2 proteins in cells EOL-1 exposed to fibronectin 
(FN) 25 µg/ml, for 60 minutes, in the presence of the compound DS70 at a concentration of 10-4, 10-5, 10-6 
and 10-7 M. Panel A, autoradiogram of a representative experiment. Panel B, quantification of the optical 
density of the individual bands. §§§ p<0.001 vs Ctrl; *** p<0.001 vs FN 60' Newman-Keuls post test after 
ANOVA. Mean ± S.E.M.; n=6. 
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Figure 6.8 Expression of phosphorylation levels of ERK 1/2 proteins in cells TF-1 exposed to fibronectin 
(FN) 1 µg/ml for 30 minutes, in the presence of the compound DS70 at a concentration of 10-4, 10-5 and 10-6 
M.  Panel A, autoradiogram of a representative experiment. Panel B, quantification of the optical density of 
the individual bands. §§ P<0.01 vs Ctrl; * p<0.05 vs FN 30' Newman-Keuls post test after ANOVA. Mean ± 
S.E.M.; n=6. 
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6.1.4 Analysis of proteins ERK 1/2 expression in cells HMC-1.1 exposed to 
fibronectin, PMA, calcimycin and DS70 
The MAPK pathway plays a crucial role in inflammatory induced responses in mast cells: thus 
modulating this system we can act directly on mechanisms regulating inflammation. It is known 
that Nf-κB   activation is modulated by MAPK, which induce phosphorylation and subsequent 
degradation   of   the   inhibitory   protein   IκB,   endogenous inhibitor that prevent NF-κB   activation   in  
cytoplasm, by keeping it in inactive form. Therefore, increase of intracellular calcium levels is an 
essential element for release of mediators from cytoplasmic granules, in addition to the activation of 
MAPK. 
Treatment with PMA and calcimycin (A23187) causes activation of cells HMC-1.1 in vitro: I 
confirmed that this event activates MAPK phosphorylation. Addition of DS70 to cells prior to these 
activators counteracts changes in ERK1/2 phosphorylation. As shown in figure 6.9, western blot 
analysis confirms an increase of ERK1/2 phosphorylation as consequence of the treatment with 
PMA and calcimycin. Concomitant addition of fibronectin further increases phosphorylation levels, 
implying a some way additive mechanism of stimulation. Pre-treated cells with DS70 at the 
concentration of 10-5 M showed a reduction of ERK1/2 phosphorylation (Figure 6.9). 
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Figure 6.9 ERK 1/2 phosphorylation in HMC-1.1 cells exposed to PMA 100 nm and calcimycin 1 µM in the 
presence or absence of FN or compound DS70 at a concentration of 10- 5 M and 10-6 M. Panel A, 
autoradiogram of a representative experiment. Panel B, quantification of the optical density of the individual 
bands. *** P<0.001 vs CTRL (Newman-Keuls test after ANOVA). * P < 0.05 vs PMA, calcimycin and 
fibronectin. Mean ± S.E.M.; n=5. 
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6.1.5 Analysis of T-cell or PMA/calcimycin induced mast cell degranulation 
levels after exposure to DS70 
In agreement with other studies, I observed a significant increase in the percentage of β-
hexosaminidase release following Jurkat T-cell contact, reaching a value of 16.2 %. DS70 (10-6M) 
reduces this release to 11.4 %. This effect seemed to be lost at final concentration equal to 10-5 M 
(Figure 6.10, panel A).  
With regards to PMA and calcimycin mediated degranulation, cells were pre-treated for 30 minutes 
at 37 °C with DS70 at concentrations 10-5M, 10-6M and 10-7M, and then exposed to PMA and 
calcimycin for 60 minutes at 37 °C. Data reported in the graph below can be explained as it follows: 
percentage of degranulation relative to positive control (only PMA and calcimycin) is around 44 %. 
After pre-treatment with DS70, the entity of the degranulation is reduced following a trend 
concentration-dependent; in fact there is a value equal to 25.7 % for DS7 10-5 M, to 23.4 % for 
DS70 10-6 M and to 20.2 % for DS70 10-7 M (Figure 6.10, panel B).  
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Figure 6.10  Panel A, Effect  of  PMA  activated  T  cells  (J*)  on  β-hexosaminidase release by HMC 1.1 cells. 
Cells were pre-t reated with DS70 10-5 M and 10-6 M. Mediators in supernantants of the co-coltures were 
measured at 22 hours of incubation; B Effect of PMA, calcimycin and DS70 10-5 M, 10-6M e 10-7M on          
β-hexosaminidase release by HMC 1.1 cells. Degranulation is expressed as percentage of the cells            
total mediator content obtained by lysis of cell with Triton X-100. Mean ± S.E.M.; n=5. 
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6.2 IN VIVO RESULTS 
6.2.1 Effect of DS70 in allergic conjunctivitis induced by ovalbumin in 
guinea pigs 
 
Guinea pigs were actively immunized by intraperitoneal injection of ovalbumin and 4 weeks later 
were challenged with ovalbumin instilled into the conjunctival sac. In guinea pigs treated with the 
vehicle+ovalbumin, one  and two hours after challenge, during the early phase ocular reaction, 
swelling of the eyelids and chemosis were more marked than in controls treated with the vehicle 
alone and not exposed to ovalbumin. During the early phase reaction, clinical observations also 
revealed typical symptoms of allergic conjunctivitis: tearing and discharge, conjunctival redness, 
chemosis and lid eversion. These symptoms persisted at least 6 hours showing a progressively 
decreasing reaction; 24 hours after challenge, the conjunctiva did not present any relevant clinical 
symptom. 
Clinical scores were significantly increased from 1 hours up to 6 hours after ovalbumin challenge, 
with a maximum at 2 hours (Figure 6.11). DS70 induced a significant reduction of the clinical score 
compared with ovalbumin (OVA): in particular, it must to be noted that 6 hours after challenge, 
during the late phase of allergic conjunctivitis, the maximum reduction in the severity of 
conjunctival symptoms was observed. As shown in figure 6.11, 24 hours after ovalbumin challenge, 
clinical scores of guinea pigs treated with vehicle+OVA or OVA+DS70 0.1% were returned to the 
pre-challenge values and no significant eye alteration was noted.  
 
6.2.2 Effect of DS70 0.1% eye drops on eosinophils peroxidase activity in 
ophthalmic lavage fluid (OLF) and conjunctiva 
 
I chose to evaluate eosinophil peroxidase activity in ophthalmic lavage fluid (OLF) and in 
conjunctiva sections, taken as an indicator of eosinophil infiltration. 
The adopted experimental model allows the evaluation of clinical and cytologic aspects of allergic 
conjunctivitis induced in the guinea pig. According to previous studies, it has been reported that 
allergen instillation into the conjunctival sac of sensitized guinea pigs induces an immediate 
hypersensitivity reaction that is biphasic. An early phase reaction (EPR), characterized by 
periorbital swelling, conjunctival edema and conjunctival redness, occurs within minutes of allergen 
challenge and reaches a maximum at 0,5 hours.  The subsequent inflammatory response, termed the 
late phase reaction (LPR), occurs 6-10 h after a single antigen challenge. The LPR is sustained 
Chapter 6 - Results 
68 
 
locally by a cellular inflammatory reaction and is characterized by accumulation in the conjunctival 
substantia propria of eosinophils, neutrophils and lymphocytes up to 24 hours after the antigen 
challenge and when the clinical signals of allergic reaction are no longer present. Eosinophil 
peroxidase activity was measured in tears collected after ovalbumin exposure and treatment with 
compound under examination (Figure 6.12). DS70 0.1% was all effective in reducing tear 
eosinophil accumulation, evaluated indirectly by eosinophil peroxidase activity, with the same 
noticeable activity at 2, 4, 6 and 24 hours. I was able to confirm that eosinophil peroxidase activity 
increased proportionally after antigen challenge in ovalbumin-treated guinea pigs using conjunctiva 
sections, whereas there was a significant reduction in DS70-treated animals. Again, DS70 0.1%, 
administered 30 minutes in advance to ovalbumin, was effective in reducing eosinophil infiltration 
in the guinea pig conjunctiva.  
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Figure 6.11  Effects of DS70 on conjunctival symptoms induced by ovalbumin in guinea pigs. DS70 eye 
drops were administered to guinea pigs actively immunized by intraperitoneal injection of ovalbumin (OVA) 
and 4 weeks later challenged with OVA (30 μl of 2.5% solution) instilled into both eyes; 30 and 10 min 
before this challenge DS70 0,1% or the vehicle were instilled into both eyes (30 μl/eye). Controls received 
the vehicle alone and were not treated with OVA. Each group comprised five guinea pigs, and the score was 
based on changes before and 1, 2, 4, 6 and 24 h after challenge for the symptoms of itching, swelling, 
redness, and lid eversion as described under Methods. Data are presented as mean ± standard error of the 
mean, n=10 (both eyes were evaluated). *p<0.05 vs OVA. Abbreviations: No immunization represents 
controls; OVA represents ovalbumin. 
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Figure 6.12 Panel A, eosinophil peroxidase (EPO) activity in ophthalmic lavage fluid (OLF). Effect of DS70 
eye drops suspension (0.1 %, 30 μL/eye) administered 30 minutes before antigen challenge on eosinophil 
peroxidase levels in ovalbumin-sensitised guinea pigs. Panel B, effect of DS70 on conjunctival eosinophil 
peroxidase levels 24 hours after topical challenge with OVA. Control guinea-pigs were not treated with 
ovalbumin. Values are the mean ± SEM of three values per each group. **p<0.001 vs ovalbumin. 
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6.2.3 Effect of DS70 0.1% eye drops on conjunctival CCL5, CCL11, IL-1E, 
IL8 mRNA levels 
 
Ovalbumin challenge induces, 24 hours later, a significant elevation of mRNA levels of CCL5, 
CCL11,  IL-1E and IL8 in tarsal conjunctival specimens. DS70, administered 30 minutes in advance 
to ovalbumin, was effective in the same way in reducing mRNA levels of CCL5, CCL11 and IL-1E 
(Figure 6.13). 
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Figure 6.13  Effect of DS70 0.1% eye drops suspension (30 μL/eye), administered 30 minutes before antigen 
challenge, on conjunctival cytokine/chemokine mRNA levels. Control guinea-pigs were not treated with 
ovalbumin. Values are the mean ± SEM of three values per each group. **p<0.001 vs vehicle+OVA. 
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6.2.4 DS70 pre-treatment effects in histological sections: immunostaining 
for  α4 subunit and Giemsa staining for mast cells degranulation 
To confirm any involvement of integrin α4 in the allergic ocular response, I performed           
immunohistochemical analysis on conjunctival sections with aim to evaluate expression levels of  
integrin α4 subunit. Histological analysis done in guinea pigs sacrificed 24 hours after ovalbumin 
challenge, showed elevated levels of this protein in correspondence of conjunctival outer edges, in 
comparison with basal levels observed in controls, not immunized animals. Black arrows indicated 
hot spot of expression levels after ovalbumin challenge. Finally, pre-treatment with DS70 0.1% 
decreased integrin expression: levels of α4 integrin expression were comparable to untreated 
animals (Figure 6.14, panel A). Furthermore, it is also possible to observe reduction of mast cells 
degranulation with Giemsa staining In sections correspondent to treatment with compound, I could 
observe a poor number of degranulated mast cells (Figure 6.14, panel B). 
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Figure 6.14 Photomicrographs of the conjunctiva 24 hours after topical challenge with ovalbumin and pre-
treatment with DS70.  Panel A, effects of compound on  conjunctival   levels  of  α4 integrin subunit 24 hours 
after topical challenge. Not immunized animals showed basal levels of expression, as expected. Black arrows 
in panel A indicated hot spot of expression.  Panel B, effects of compound on mast cells degranulation 24 
hours after topical challenge. Black arrows revealed presence of preformed granules, typical marker of 
happened degranulation. DS70 0.1% is able to prevent this release. 
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7. DISCUSSION AND CONCLUSIONS 
 
Inflammation is a complex response to a local injury or trauma involving various immunocytes and 
numerous mediators. The assembly of the inflammatory response would be impossible without the 
controlled migration of immune cells, of which cell adhesion molecules such as integrins are key 
components for migration and activation. Integrins are heterodimeric molecules and cell surface 
transmembrane glycoproteins that mediate cell-cell and cell-matrix interactions. Among these 
molecules, I focused my attention on integrin α4β1. It requires the interaction with its ligands 
fibronectin, vascular cell adhesion molecule 1 (VCAM-1), and mucosal addressin cell adhesion 
molecule 1. Integrin α4β1 is an important component in immune functions, playing a role in 
lymphocyte differentiation and homing, as well as in tissue-specific migration during inflammation 
[Alon et al., 1995]. α4   integrins,   including   α4β1 and   α4β7,   have   tightly   regulated multi-step 
functions during rolling and arrest of leukocytes on the endothelium [Berlin et al., 2005].  
Integrin α4β1 is implicated in the pathogenesis of autoimmune diseases and chronic inflammation 
such  as  multiple  sclerosis,  Crohn’s  disease,  asthma,  stroke, rheumatoid arthritis, and inflammatory 
bowel disease [Hyun et al., 2010], but also in several allergic diseases [Pelaquini et al., 2011]. In 
allergic subjects a persistent or repetitive exposure to allergens, which are intrinsically innocuous 
substances frequently found in the environment, results in a chronic allergic inflammation. This in 
turn produces long-term changes in the structure of the affected organs and substantial 
abnormalities in their function. It is, therefore, important to understand the characteristics and 
consequences of acute and chronic allergic inflammation, and in particular to explore how integrin 
α4β1 contributes to this event and how it can be modulated using small antagonist molecules. 
Therefore, VLA-4 has been therapeutically targeted by antagonists such as blocking antibodies 
(Natalizumab). However, the inherent limitations of antibody therapy, high cost, potential 
immunogenicity, and the requirement for intravenous administration, strongly spurred efforts to 
develop ligand mimetic small molecules [Dattoli et al., 2013]. There are problems connected with 
the use of natural peptides, due to the low stability against proteolysis, resulting in a short duration 
of in vivo activity, and in a low bioavailability. One way to overcome these disadvantages is the 
employ modified peptides named peptidomimetics. This study focused on pharmacological 
characterization of a library of peptidomimetics synthetized by Professor Luca Gentilucci’ group 
(Department of Chemistry, University of Bologna). The structures of the peptidomimetics were 
designed on the basis of the models developed by 3D-QSAR analysis of large libraries of 
compounds containing diphenylureas, or other substituted aromatic groups. Starting from the 
assumption that well determined  pharmacophores are essential for the interaction with our target, 
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structures of this peptidomimetic inhibitors of integrin α4β1 integrin are all based on  a rigid central 
scaffold,  β-amino acid residues, and partially modified retro-sequence. 
First of all, inhibitory activity of all library of compounds was assessed in vitro through cell 
adhesion assays in Jurkat E6.1 cell line and a high-throughput screening (HTS) assay (scintillation 
proximity assay). This latter assay involves several steps to set up: purification of isolated integrin 
receptor from cultured cells, fibronectin labeling with 125I (radioactive ligand), and optimization of 
different reagent concentrations and time incubation through establishment of a saturation curve.  
Several of these compounds exhibit IC50 values extending from micromolar to nanomolar range. 
The best results have been obtained for compounds having the pharmacophores separated by 14 
bonds, such as DS70. In fact, this compound shows has an IC50 value equal to 0,022 µM (± 0,003) 
in SPA assay and to 0,0020 (± 0,0005) µM in VCAM-1 mediated cell adhesion assay. This 
compound bears diphenylurea moiety   to   interacts   with   α   subunit,   a   beta   prolin,   and a glycine 
carrying a carbossilic group.  
DS70, as integrin α4β1 antagonist, has been investigated to define its selectivity and specificity, in 
different cell lines expressing integrins, and in parallel, to analyze its effects on three principal 
component of inflammatory response: lymphocytes, mast cells and eosinophils.   
Futher adhesion assays in Jurkat E6.1 cell line have allowed us to understand that the inhibition of 
cellular adhesion determined by DS70 is mediated only from integrin α4β1 and not from integrin 
αLβ2, both expressed on such cells. 
DS70 is able to inhibit cellular adhesion in an eosinophilic cell line, using as ligand both VCAM-1 
and FN. DS70 results to be a dual antagonist of α4 integrin family, because it also exerts inhibitory 
action towards integrin α4β7, expressed in the cellular line RPMI8866. Albeit DS70 causes a 
significant reduction of cellular adhesion. It is less potent towards this integrin subtype. On the 
contrary, DS70 is a highly specific compound  as  it  doesn’t  display  any  significant  activity towards 
integrin α5β1, integrin αvβ3 and integrin α9β1, as shown in cellular adhesion assay in cell lines 
expressing these specific integrins. 
After these experiments, I moved further to explore the ability of DS70 to modulate integrin 
signaling. Integrin receptors form structural and functional linkages between the extracellular 
matrix (ECM) and intracellular cytoskeletal linker proteins. Cell signaling mediated by 
integrin/ECM interactions is also integrated by cellular responses to growth factor signaling to 
regulate cellular proliferation, cytoskeletal reorganization, and other responses necessary for cell 
survival. Integrin receptors do not possess any kinase domains but they can activate a number of 
intracellular signaling pathways following extracellular adhesive interactions. Clusters of 
integrin/extracellular matrix interactions form focal adhesion points, concentrating together 
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cytoskeletal components and signaling molecules within the cell.  The cytoplasmic tail of integrins 
serve as a binding   site   for   α-actinin and talin which then recruit vinculin, a protein involved in 
anchoring F-actin to the membrane.  In addition to actin polymerization/depolymerization, ligand 
binding to integrin receptors results in the talin-mediated oligomerization of FAK (Focal Adhesion 
Kinase). Focal adhesion kinase is best known for its role as an integrin-stimulated protein-tyrosine 
kinase. FAK is recruited to sites of integrin clustering via interactions of its C-terminal domain with 
integrin-associated proteins such as talin and paxillin. FAK contains a central kinase domain, C-
terminal proline-rich regions that serve as binding sites for Src homology 3 (SH3) domain-
containing proteins, and a protein 4.1, Ezrin, Radixin, Moesin domain (FERM)  that acts to regulate 
FAK kinase activity through an auto-inhibitory mechanism [Schlaepfer et al., 2007]. The Tyr397 
autophosphorylated FAK binds and activates Src and Fyn which in turn phosphorylate the FAK-
associated proteins paxillin, tensin, and p130CAS. In addition, phosphorylated FAK has been 
shown   to   phosphorylate   PI3K,   PLCγ,   and  GRB7 leading to their activation. Activation of PI3K 
links integrin activation with the Akt signaling pathway for activation of cell survival mechanisms 
[Meng et al., 2009]. Phosphorylation of FAK at Tyr925 occurs by Src, thereby forming a complex 
with GRB2 and SOS, leading to the activation of Ras.  Ras can function to activate numerous 
kinases including MEKKs, PAKs, MEKs, JNK, and SAPK. These kinases are key regulators of 
gene expression via the phosphorylation of multiple transcription factors including c-Myc, Elk1, 
Jun, and SRF (Serum Response Factor) [Harburger et al., 2009].  
Therefore, I investigated any modulatory effect of compound DS70 on ligand-induced 
phosphorylation of FAK (Tyr197) in Jurkat E6.1 cells and of ERK 1/2 in all cell lines, expressing 
α4β1 integrin. I set up an in vitro model, starting from preliminary experiments performed with other 
integrin receptor [Tolomelli et al., 2013]. First of all, I observed that VCAM-1-induced FAK 
phosphorylation in Jurkat cells after 30 minutes of incubation, and FN-induced FAK or ERK 1/2 
phosphorylation in Eol-1 and TF-1 cell line after 60 minutes and 30 minutes, respectively; thus, this 
assay appeared to be quite robust. Then, I was able to confirm that pre-treatment with different 
concentrations of DS70 can prevent, in a dose dependent manner, FAK and ERK 1/2 
phosphorylation. Optimal drug concentrations for each cell line were selected, given that integrin 
responsiveness strongly depends on cellular context. However, micromolar or submicromolar doses 
(10-5 or 10-6 M) revealed to be in general the most efficacious: these concentrations appeared to be 
interesting for a possible systemic administration of this compound in vivo. 
 
Various integrins are expressed on mast cells and constitute an essential prerequisite for the 
accumulation of the cells at sites of inflammation. In order to clarify a potential contribution of 
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inflammatory cytokines to this process, I have studied the modulation of integrin expression and 
adhesion of immature human mast cells (HMC-1) to extracellular matrix proteins. 
There is increasing evidence that adhesive interactions between mast cells and extracellular matrix 
(ECM) proteins play a major role in regulating anchorage, migration, differentiation, and function 
of these cells in various tissues. This concept is supported by the demonstration of the occurence of 
adhesion molecules on resting and/or activated mast cells [Metcalfe et al., 1997; Henz et al., 2001]. 
Furthermore, there is increasing evidence that exists a specific regulation of the expression and 
function of these molecules in normal tissue, under physiologic conditions or in various 
inflammatory states where the number of mast cells is increased. 
Mast cells (MCs) are critical effector cells of both innate and adaptive immunity. In vertebrates, 
mast cells are widely distributed throughout vascularized tissues, particularly our body surfaces 
exposed to the external environment, including skin, airways, and gastrointestinal tract. Mast cells 
are considered to be one of the first cells of the immune system capable to interact with 
environmental antigens, toxins, or invading pathogens [Galli et al., 2010]. 
Like other myeloid cells, MCs derive from bone marrow–derived progenitors. These are 
mononuclear cells that lack the characteristic secretory granules of their mature counterparts. As 
assessed by cytofluorographic criteria, bone marrow–derived progenitors express high  levels  of  α4- 
and β1-integrin. The high expression of α4β1 subunits and PSGL-1 by these cells suggests that they 
may interact with VCAM-1 and the selectins, respectively. Immobilized soluble VCAM-1, as well 
as both recombinant P- and E-selectins, supported their attachment across a range of flow 
conditions in vitro.  The adhesion to VCAM-1 was blocked nearly completely by anti–VCAM-1 
and anti–α4-integrin Abs, implying complete dependence on the α4β1 and/or α4β7 integrins for this 
event [Boyce et al., 2002]. Fully differentiated mast cells purified from human skin and uterus also 
express α4β1 [Columbo et al., 1995]. Firstly,  our  data  attest  α4 subunit presence in HMC 1.1 cells, a 
well established and widely used human cell line exhibiting many characteristics of mast cells. As 
reported in the literature, in vitro cellular adhesion of this cell line to VCAM-1 is mediated by 
integrin α4β1 and is abrogated with pre-incubation of cell line with DS70, in a dose-dependent 
manner.  
In 1994,  Ra and colleagues demonstrated for the first time that engagement of α4β1 and vitronectin 
receptor  (β3 integrin) promote mast cells degranulation induced by cross-linking of the high-affinity 
IgE receptor. Blocking these adhesion molecules by monoclonal antibodies remarkably reduces 
passive cutaneous anaphylaxis reaction in vivo. 
β-hexosaminidase induced mast cells release is a marker for mast cell degranulation. It is triggered 
by high affinity IgE receptor (Fc epsilon RI)-mediated stimulation, and it enhances adhesion of 
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RBL-2H3 cells (rat mast cells) to either immobilized fibronectin, or monoclonal antibodies reactive 
with integrin chain alpha 4-1, alpha 5-1 or beta 3-1.  
Fibronectin  enhancement  of  β-hexosaminidase release is inhibited by specific antibodies as well as 
by GRGDSP and DELPQLVTLPHPNHLGPEILDVPST peptides that abrogate VLA-5/VNR 
(vitronectin) and α4β1 binding to FN, respectively. In vivo, passive cutaneous anaphylaxis induced 
by IgE anti-DNP and DNP-BSA (2,4-dinitrophenylated BSA) was inhibited by concurrent injection 
of such antibodies. These results demonstrate that integrins expressed on rat mast cells bind to 
fibronectin and play an important role in regulating mast cell activation both in vitro and in vivo 
[Yasuda et al., 1995].  
A number of studies reported that blocking integrin α4β1 with specific antibodies could prevent both 
allergic early airway response (EAR) and late airway responses (LAR) and reduce the so-called 
nonspecific airway hyperresponsiveness in allergen challenged animals (rat, rabbit and sheep) 
[Rabb et al., 1994; Metzger et al., 1995; Abraham et al., 1997]. The inhibitory actions of anti-α4β1 
monoclonal antibodies (mAb) have been attributed mainly to preventing migration and/or activation 
of eosinophils and lymphocytes as well as mast cells in the sites of airway inflammation. Another 
study performed in Brown Norway rats, sensitized and challenged with ovalbumin, showed that 
treatment with a specific anti-α4β1 mAb prevents allergen-induced airway responses, the release of 
mast cell mediators, and cys-LT synthesis in sensitized Brown Norway rats [Hojo et al., 1998]. 
In this frame, my aim was to investigate whether any reduction  α4-integrin dependent of early phase 
response is related to inhibition of mast cell degranulation and inflammatory mediator release, and 
to provide a possible explanation of this. Effectively, DS70 was able to reduce  β-hexosaminidase 
levels in HMC 1.1 cells stimulated with both PMA and calcimycin and in PMA activated T-cells. 
 
Recent in vitro studies indicate that mast cells may be triggered to degranulate and release cytokines 
upon heterotypic adhesion to activated, but not resting, T cells [Inamura et al., 1998; Baram et 
al.,2001; Salamon et al., 2005]. Our results provide evidence that direct contact between cell-
surface molecules on mast cells and on activated T cell membranes is sufficient to transduce the 
stimulatory signal necessary for mast cells degranulation and to promote cytokine release, 
independent of T cell intracellular function or production of cytokines or other mediators.  
It was shown that direct contact of human mast cells with T lymphocyte membranes resulted in the 
phosphorylation of the MAPK family [Mor et al., 2010]. The MAPKs are known to play an 
important role in mediator release in human mast cells after IgE–cross-linking or on activation by 
inducers, such as SCF and TNF-α  [Rivera  et al., 2006; Wong et al., 2006]. In accordance with these 
findings, it has been reported that microparticle induced degranulation of LAD2 cells (a cell line of 
Chapter 7 – Discussion and conclusions 
77 
 
mast cells) is regulated by MAPKs, as it is abrogated by the addition of a specific inhibitor 
(PD98059) to MAPK kinase/ERK, showing a   significant   reduction   (~60%)   in   β-hexosaminidase 
levels. Given that the antagonist action of DS70 on α4β1 integrin involves the modulation of this 
signaling pathway, it could be hypothesized a possible regulation at this step. My results, therefore, 
provide new insights on the activation of HMC-1.1 mast cell that requires a diversified and complex 
intracellular regulation. However, further investigations are required to provide a complete 
explanation of this mechanism.  
 
With regards to in vivo assays, this study aimed to investigate the potential anti-allergic activity of 
DS70, specifically designed to be an α4β1 integrin antagonist in a model of allergic conjunctivitis. 
Ocular allergy represents one of the most common conditions encountered by immunolgists and 
ophthalmologists. Allergic conjunctivitis is often underdiagnosed and consequently undertreated. 
Allergic eye inflammation is a localized allergic condition that is frequently associated with rhinitis 
and occasionally with asthma but often observed as the only or prevalent allergic manifestation. The 
symptoms and signs can manifest alone in the eyelids as atopic blepharitis or contact blepharitis. 
Lid symptoms may occur together with conjunctival symptoms. Allergic conjunctivitis is the most 
common manifestation alone or together with lid symptoms. The eye is red and itchy, and there is 
lacrimation and slight discharge [Kari et al., 2012]. The possibility of curing allergic diseases is an 
essential issue for research because the medications currently used to treat these diseases, such as 
antihistamines, leukotriene receptor antagonists and glucocorticoids, only temporarily relieve 
symptoms by suppressing inflammation. Basic and clinical researches have provided a better 
understanding of cells, mediators, and immunologic events, which occur in ocular allergy. 
The severity of allergic conjunctivitis (AC) correlates primarily with the degree of eosinophil 
infiltration into the conjunctiva, which is believed to be mediated by chemokines and adhesion 
molecules. Integrin α4β1 and its ligand, vascular cell adhesion molecule (VCAM)-1, are known to 
play important roles in eosinophil infiltration, and in general in the recruitment of immune cells in 
inflammation sites.  
The expression and function of integrin α4β1 in allergic conjunctivitis have been investigated more 
in detail in recent years. Nowadays, adhesion molecules and their intracellular signals are validated 
targets to control allergic conjunctivitis [Baiula et al., 2012]. Advancement in understanding of the 
pathophysiology of ocular allergies has paved the way for the development of newer drug 
candidates, and the adhesion-based therapeutic  strategies   targeting  α4 integrin seem promising for 
ocular allergy. With regards to small molecules and similar, it is known by literature that 
levocabastine, in addition to its effects on H1 histamine receptors, binds to human integrin α4β1 and 
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prevents eosinophil adhesion to VCAM-1, FN and human umbilical vascular endothelial cells in 
vitro. In a classical model of allergic conjunctivitis, levocabastine eye drops reduced the clinical 
symptomps of the late phase reaction and the conjunctival expression of α4β1 integrin by reducing 
eosinophil infiltration [Qasem et al.,2008]. Authors hypothesized that blockade of integrin-
mediated cell adhesion might be a target of the antiallergic action of levocabastine and may play a 
role in preventing eosinophil adhesion and infiltration in allergic conjunctivitis. 
Ebihara and colleagues in 1998 have reported that in an actively sensitized  allergic 
conjunctivitis model of guinea pig, treatment with an anti α4β1-mAb was able to reduce almost 
completely eosinophil infiltration at least until 24 hours after the antigen challenge. Furthermore, 
treatment with both anti-α4β1 and anti-VCAM-1 antibodies significantly suppressed the infiltration 
of eosinophils into the conjunctiva in mice that was induced by either active immunization with 
ragweed or or adoptive transfer of ragweed-primed splenocytes [Fukushima et al., 2006]. These 
results confirm that α4β1-expressing cells infiltrate the conjunctiva and that the interaction between 
integrin α4β1 and VCAM-1 is needed for the development of allergic conjunctivitis. 
Effects on clinical score, eosinophils activity (in tears and in conjunctiva), levels of cytokines and 
chemochines  mRNA,  mast  cells  degranulation  and  α4 integrin expression, were all assessed in this 
thesis. I focused on eosinophils and mast cells, two crucial effectors of both early and late phase of 
allergic response, since these cells mediate unique cytotoxic and inflammatory effects by the 
generation, storage, and release of their granule proteins and the production of cytokines, growth 
factors, reactive oxygen species, and proinflammatory lipid mediators. Their recruitment and 
activation are regarded as crucial to the development of allergic disorders, including conjunctivitis 
[Ono et al., 2005].  
Here I report a significant reduction of clinical symptoms at a concentration of DS70 of 0,1% p/v. 
Eosinophil peroxidase levels, taken as an index of eosinophil accumulation, in tears and in tissues 
collected from guinea pigs pre-treated with DS70 and then with ovalbumin are equally decreased. 
The significant decrement of the chemokines and cytokines suggests that DS70 is capable to exert 
an influence in a relevant inflammatory response produced in the conjunctiva of sensitized guinea 
pigs by an allergen. 
I found a lower expression of α4β1 integrin in the conjunctiva of ovalbumin-sensitized guinea pigs 
treated with DS70: this might be a consequence of the reduction in recruitment and migration of 
α4β1-expressing cells to the site of allergic inflammation. It is important to note that the same effect 
is also a typical mechanism of action of levocabastine. 
I confirmed the positive effect of  DS70 eye drops on early phase and late phase reactions 
inflammatory changes induced by allergen-specific conjunctival challenge. Histamine and 
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eicosanoids are responsible for the typical early phase reaction. Mast cells also contribute to the 
synthesis and release of cytokines, chemokines and growth factors, triggering a cascade of 
inflammatory events on the surface of epithelial and endothelial cells that leads to the late phase 
reaction, with recruitment of eosinophils and neutrophils. Inflammatory cytokines may enhance the 
expression of E-selectin, ICAM-1 and VCAM-1 on the vascular endothelial cells and initiate the 
rolling of immune cells, sustaining a positive loop [La Rosa et al., 2013]. 
According to previous data in vitro, DS70’s effect on early phase reaction seems to be mediated by 
the blockade of  mast cells activation. I confirmed in vivo what observed before in in vitro studies: 
DS70 is able to prevent mast cells degranulation and, therefore, the consequent release of preformed 
granules in conjunctival tissue sections. 
In ovalbumin-sensitized guinea pigs, this compound almost completely prevented conjunctival 
symptoms and this effect lasted up to 24 hours. Therefore, compound DS70 administrated topically 
may persist at an adequate conjunctival concentration for long periods of time, phenomenon that 
suggests an increased bioavailability in tissues than normal peptides. 
Definitively, DS70 possesses potent and sustained antiallergic activity in preventing ocular 
inflammatory responses to ovalbumin exposure in sensitized guinea pigs. I propose that DS70 
exerts a pleiotropic role as an antiallergic agent: it can interfere at different levels with 
accumulation and activation of immune cells (eosinophils, mast cells and leukocytes).  
Late phase response is inhibited by DS70 pretreatment. Although it is possible that inhibition of the 
early phase which is often considered proemial to the late one accounts for the reduction of the 
latter (showing an inhibitory action on mast cells), an independent effect on the late phase could be 
also possible. Since eosinophils and lymphocytes are strikingly involved in the development of the 
late phase, the decrease in the magnitude of this response could result from the effect of DS70 on 
activation  of  these  cells.  A  fine  “tuning”  of  recruitment  and  activation  of  immune  cells  can  be  taken  
into account to explain DS70 mechanism of action. DS70 can represent without any doubt a lead 
compound in the field of anti-inflammatory drugs. 
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